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 Candida albicans is an opportunistic pathogen that can cause infections that range 
from mild rashes to life-threatening bloodstream infections. The antifungal drug 
resistance of some Candida strains and the deficiencies in the current methods used to 
identify infection-causing species call for improvements in treatment and diagnosis of 
Candida infections.  
 Towards improving therapeutics, the antimicrobial peptide histatin 5 (Hst-5) was 
studied. Hst-5 is a salivary peptide with strong antifungal activity against C. albicans. 
However, the pathogen produces a family of secreted aspartic proteases (Saps), some of 
which can degrade and inactivate Hst-5. Of the family, Sap2 and Sap9 have been 
previously shown to degrade Hst-5. Variants of Hst-5 with one or two amino acid 
substitutions were designed and tested to evaluate the effect on the proteolysis of the 
peptide by the Saps. The results showed that even a single amino acid substitution results 
  
in a significant reduction or enhancement of proteolysis by Saps. The K17R and K17L 
modifications led to significantly enhanced resistance to proteolysis to both Saps. The 
substitutions also had site-, residue-, and Sap-dependent effects and the proteases have 
preferences for certain amino acids at the substitution sites, such as leucine at the 13th 
residue by Sap9. The substitutions affect not only the cleavage at the substitution sites but 
also the degradation of the peptide as a whole. Some of the modifications (K11R, E16R, 
E16L) also led to enhanced antifungal activity. Furthermore, combination of two 
modifications (K11R-K17R) resulted in a peptide with both enhanced proteolytic 
resistance to Saps and enhanced antifungal activity, demonstrating its potential as an 
alternative therapeutic.  
 Towards improving diagnostics, a purification-free method to immobilize single-
chain variable fragment (scFv) antibodies was developed. Two biotinylation tags—the 
biotin carboxyl carrier protein or the AviTag minimal sequence—were genetically fused 
to scFvs to allow for in vivo, site-specific biotinylation by endogenous Escherichia coli 
biotin ligases during protein expression. scFvs with different frameworks and antigens 
were all successfully immobilized directly from cell lysates onto streptavidin-coated 
plates, and the immobilized scFvs maintained their functionality for over 100 days at 
4 °C. The simplicity and robustness of this method make it a suitable approach to create 
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 As a fungal species, C. albicans has a multi-layered cell wall composed of an inner 
layer of polysaccharides, which include β-1,3-glucans, and an outer layer of 
mannoproteins [3, 5]. Cell wall proteins are non-covalently or covalently linked directly 
to β-1,3-glucans or indirectly through a glycosylphosphatidylinositol (GPI) remnant [5]. 
Expression of GPI-linked proteins such as Hwp1 is one of the virulence factors for C. 
albicans, and these virulence factors also include phenotypic switching opaque cells and 
secretion of hydrolytic enzymes [6].  
 
1.1. Toward therapeutic improvements 
 Some treatments for Candida infections, such as the antifungal drugs amphotericin B 
and fluconazole, are available, but the options are few and they have limitations. For 
example, amphotericin B has toxicity to the kidneys and can cause kidney injuries in up 
to 50% of treated patients [7]. There is also an increasing prevalence of drug-resistance 
stains of Candida and, in fact, the Centers for Disease Control and Prevention listed 
fluconazole-resistant Candida infections as a serious threat to human health in its 2013 
report on antibiotic resistance threats in the United States [8]. The limitations of the 
current treatments call for new therapeutic methods and one approach is to consider the 
role virulence factors of Candida infections.  
1.1.1. Secreted aspartic proteases (Saps) 
 One of the key virulence factors of C. albicans is the secretion of hydrolytic enzymes, 
which are though to aid infection through degradation cell surfaces and host immune 
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produced as a larger preproenzyme and is ultimately transported by the secretory pathway 
[10] to be anchored on the cell wall or released to the extracellular space.  
 The Saps range in size from 36 to 52 kDa (Table 1.1). When samples of the purified 
recombinant Saps are run on sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) gels, Sap2, Sap4, and Sap7 – 9 show multiple distinct bands [9, 16, 17], 
likely due to internal cleavage or post-translational processing of the Saps. Some of the 
Saps have N-glycosylation sites, with Sap9 and Sap10 containing the most with five and 
eight sites, respectively [9]. In addition to size and N-glycosylation sites, the Saps differ 
in their active pH range; Sap1 – 3 and Sap8 prefer lower pH while Sap4 – 7, and Sap 9 – 
10 prefer higher pH [16-18]. In particular, Sap7, Sap9, and Sap10, have higher activity 
closer to physiological pH. Consideration of the roles of Saps that are most active at 
physiological pH will be important as new treatments need to be active at that pH.  
 
Table 1.1. Properties of the ten secreted aspartic proteases. 
Protease 
Molecular 





Sap1 39-40a 3.5 - 6.0 - + [10, 16, 17] 
Sap2 38-49a.b 2.5 - 5.5 - + [10, 16, 17] 
Sap3 37-42a 2.0 - 5.0 - + [10, 16, 17] 
Sap4 39b 4.0 -7.0 + + [16, 17] 
Sap5 36 3.0 - 7.0 - + [16, 17] 
Sap6 38 3.0 - 7.0 + + [16, 17] 
Sap7 52, 15b 3.5 - 7.5 + - [17] 
Sap8 36b 2.0 - 5.0 + + [17] 
Sap9 44, 11b 3.5 - 8.0 + Partial [17, 18] 
Sap10 42 4.0 - 8.0 + Partial [17, 18] 
a Range in size due to molecular mass estimated from gels.  
b Although multiple bands were observed for these Saps, estimated size of other band were only 








1.1.3. Substrate specificity and proteolytic preferences of Saps 
 Knowledge of proteolytic activity of Saps will be valuable as it is desirable that new 
treatment method is not susceptible to the Saps and inactivated by them. The Saps are 
able to cleave various human proteins, and studies on the substrate specificity of the Saps 
have focused most extensively on Sap2. Sap2 has a broad specificity that includes 
immune host proteins, such as immunoglobulin A, lactoferrin, and antimicrobial peptides 
[10, 19-21]. The rest of the Saps also cleave antimicrobial peptides [19-21], and Sap9 – 
10 additionally cleave covalently bound cell wall proteins [18].  
 To gain a more detailed understanding of how the Saps cleave their substrates, studies 
have analyzed various libraries of peptides to elucidate the amino acid preferences for 
each Sap. The library studies agree that, in general, the Saps have a preference for basic 
amino acids or large hydrophobic amino acids at the cut sites [17, 18, 22]. More 
explicitly, Sap1 – 6 and Sap8 appear to prefer residues such as phenylalanine, leucine, 
and tyrosine [17, 22] while Sap7, Sap9, and Sap10 have a more specific preference for 
methionine, arginine, or histidine, respectively [17]. However, these peptide library 
studies are limited to varying the residue that is either immediately N-terminal or 
immediately C-terminal to the cleavage site, while leaving the other residue fixed [17, 
22]. Thus, they do not account for the potential roles of residues further way from the cut 
site. Furthermore, the peptides typically consist of random amino acid sequences with no 





1.1.4. Histatin 5 
 One of the common mucosal surfaces for C. albicans to colonize is inside the oral 
cavity. The oral cavity contains various salivary proteins that help keep C. albicans at 
commensal levels by clearing the cells or killing them. Immunoglobulin A and mucins 
help clear C. albicans through swallowing by binding to the cells and aggregating them 
[23]. Others proteins like antimicrobial peptides, which include the histatin peptides, 
eliminate the pathogen through their antifungal properties [23, 24]. However, the 
histatins, particularly histatin 5 (Hst-5), are cleaved by some of the Saps and lose their 
activity [20, 25]. 
 Histatins are a family of histidine-rich peptides that have antifungal activity against 
C. albicans [26]. Histatin 1, histatin 3, and histatin 5 (Hst-5) are the major histatins 
secreted by parotid and submandibular glands [27]. The 24-amino acid Hst-5 (Figure 1.3) 
is a proteolytic fragment of histatin 3 [28] and has the strongest antifungal activity against 
C. albicans [27]. Whole saliva contains 15 – 30 μM of Hst-5 [29], however, reduced 
levels of Hst-5 have been reported in HIV-positive patients [30] and may contribute to 
their high susceptibility to oral candidiasis.   
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
D S H A K R H HG Y K R K F H E K H H S H R G Y
Antifungal fragments  
Figure 1.3. The amino acid sequence of Hst-5. The antifungal fragments of the sequence are 
underlined. 
 
 Unlike some other common antimicrobial peptides, Hst-5 does not act on C. albicans 




5 binds to the cell wall heat shock protein Ssa2 [32] and is translocated into the cell in a 
separate, energy-dependent manner through the fungal polyamine transporters Dur3 and 
Dur31 [29]. The exact mechanism of action is still being studied, but the uptake of Hst-5 
results in ion imbalance (especially of K+) and volume loss that eventually causes cell 
death [3, 29]. 
 To determine the section of the peptide sequence that contributes to the antifungal 
activity, the activities of truncated Hst-5 peptides (Table 1.2) have been previously tested. 
The N-terminal fragments had no activity, and, initially, the C14 fragment (residues 11 – 
24) was identified as the minimal sequence required for antifungal activity against 
C. albicans [33]. However, a later study found that the P-113 fragment (residues 4 – 15) 
has antifungal activity even greater than Hst-5 [34]. These findings show that while the 
whole peptide sequence is not required for the antifungal activity, the active fragment of 
the peptide appears to depend on what section of the peptide is truncated and may be 
influenced by surrounding amino acids. 
 





1   4    8   12  16  20 24 
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y  [33] 
N16 D S H A K R H H G Y K R K F H E         Less than Hst-5 [33] 
C16          G Y K R K F H E K H H S H R G Y Same as Hst-5 [33] 
M10        H H G Y K R K F H E         Very weak  [33] 
C14/dh-5           K R K F H E K H H S H R G Y Similar to Hst-5 [33, 35] 
C12             K F H E K H H S H R G Y Less than Hst-5  [33] 
C10               H E K H H S H R G Y Weak  [33] 
P-123 D S H A K R H H G Y K R K F           Not active [34] 
P-103     K R H H G Y K R K F H E K H H S H R   Less than Hst-5 [34] 
P-112 D S H A K R H H G Y K R              Not active [34] 
P-113    A K R H H G Y K R K F H          More than Hst-5 [34] 
P-114       H H G Y K R K F H E K H       Not active [34] 
P-115          Y K R K F H E K H H S H    Not active [34] 
P-116             K F H E K H H S H R G Y Not active [34] 
P-117     K R H H G Y K R K F H          Less than Hst-5 [34] 
P-118    A K R H H G Y K R K F           Less than Hst-5 [34] 
P-119    A K R H H G Y K R K            Not active [34] 




1.1.5. Amino acid substitutions and antifungal activity  
 Once the antifungal fragments were identified, the amino acids within the fragments 
were modified to gain a better understanding of how the residues within the sequences 
contribute to the antifungal activity. The amino acid substitutions were done to the full 
Hst-5 sequence or truncated fragments. For the full-length Hst-5, the importance of the 
charge, hydrophobicity, and the imidazole rings of the amino-acid side chains and the 
potential for the peptide to form an α-helical structure were tested (Table 1.3). Mutation 
of one or four charged amino acids to glycine [36] or alanine [37]  within the active 
fragment 11 –24 led to a significant decrease in antifungal activity, which suggests that 
the charged side groups of some, if not all, of the modified residues—R12, K13, H15, 
E16, K17, H18, H19, H21, R22—play a role in the antifungal activity. Specifically, the 
reduced activity from the single E16G substitution in pHst5ΔGlu shows that the glutamic 
acid at that site is important for the antifungal activity [36]. K13 is another crucial site, as 
the K13T (m21) and K13E (m71) modifications led to a decrease in activity [38]. On the 
other hand, the imidazole side chains at H19 and H21 do not a play significant role in the 
antifungal activity (m12 and m70), though the positive charge at H21 may be vital as the 
substitution of both histidine residues to proline (2P)  leads to reduced antifungal activity 
[39]. Additionally, the α-helical structure of the peptide in non-aqueous conditions [40, 
41] does not appear to be important for the antifungal activity. Situ et al. inserted one to 
three prolines into the sequence to disrupt the α-helical structure, and the peptide with the 
most proline insertions (3P) still had activity comparable to original Hst-5, which 
suggests the α-helical structure does not play a significant role. Overall, the residue 




imidazole rings are not vital for the antifungal activity of the intact peptide, but the 
charge of the residue is important. 
 
Table 1.3. One to four amino acid substituted Hst-5 and antifungal activity compared to Hst-5. 
Name
1 4 8 12 16 2 0 2 4
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y
pHst5∆His - - - - - - - - - - - - - - G - - G G - G - - - Not active [36]
pHst5∆Glu - - - - - - - - - - - - - - - G - - - - - - - - Less than Hst-5 [36]
pHst5∆Lys/Arg - - - - - - - - - - - G G - - - G - - - - G - - Less than Hst-5 [36]
reHsn-5 G - - - - - - - - - - - - - - - - - - - - - - - Similar to Hst-5 [38]
m1 - - - - - - - - - - - I - - - - - - - - - - - - Similar to Hst-5 [38]
m2 - - - - - - - - - - - I - - - - N - - - - - - - Similar to Hst-5 [38]
m12 - - - - - - - - - - - I - - - - - - - - L - - - Similar to Hst-5 [38]
m21 - - - - - - - - - - - - T - - - - - - - - - - - Less than Hst-5 [38]
m68 - - - - - - - - - - - - E - - - - - - - - G - - Less than Hst-5 [38]
m70 - - - - - - - - - - - - - - - - - - P - R - - - Similar to Hst-5 [38]
m71 - - - - - - - - - - - - E - - - - - - - - - - - Less than Hst-5 [38]
F14A/H15A - - - - - - - - - - - - - A A - - - - - - - - - Less than Hst-5 [37]
F18A/H19A - - - - - - - - - - - - - - - - - A A - - - - - Less than Hst-5 [37]
1P - - - - - - - - - - - - - - - - - - - - P - - - Less than Hst-5 [39]
2P - - - - - - - - - - - - - - - - - - P - P - - - Less than Hst-5 [39]




 As was done for the intact peptide, the contribution of amphipathicity, positive 
charge, and hydrophobicity of the antifungal fragments to the antifungal activity was 
studied through amino acid modifications (Table 1.4). The enhancement of the lateral 
amphipathicity of the dh-5 fragment (residues 11 – 24 of Hst-5) by substitution of single 
lysine, leucine, or phenylalanine—based on position in helical-wheel—had  no effect, but 
multiple substitutions (dhvar1 and dhvar2) led to enhanced activity [35]. Further 
modification of glutamic acid to lysine increased the overall charge of dhvar1 and dhvar2 
and led to some improvement in the antifungal activity, as well [42]. Another peptide, 




when it forms an α-helix[42]. Surprisingly, dhvar5 showed improved antifungal activity 
not only in the low ionic buffer used for the other fragments, but also in highly ionic 
phosphate buffered saline (PBS) [42]. For the dh-5 fragment, multiple modifications that 
significantly change the sequence of the fragment were required for amino acid 
substitutions to have an effect on the antifungal activity.  
 
Table 1.4. Amino acid substitution of dh-5 and P-113 Hst-5 fragments and antifungal activity 




1 4 8 12 16 20 24
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y
dh-5 K R K F H E K H H S H R G Y
dh13L - - L - - - - - - - - - - - Similar to dh-5 [35]
dh15K - - - - K - - - - - - - - - Similar to dh-5 [35]
dh17L - - - - - - L - - - - - - - Similar to dh-5 [35]
dh18L - - - - - - - L - - - - - - Similar to dh-5 [35]
dh18K - - - - - - - K - - - - - - Similar to dh-5 [35]
dh19K - - - - - - - - K - - - - - Similar to dh-5 [35]
dh21F - - - - - - - - - - F - - - Similar to dh-5 [35]
dh23K - - - - - - - - - - - - K - Similar to dh-5 [35]
dhvar1 - - L - K - L K F - L - K - More than dh-5 [35]
dhvar2 - - L - K - L L F - L - K - More than dh-5 [35]
dhvar3 - - L - K K L K F - L - K - More than dh-5 [42]
dhvar4 - - L - K K L L F - L - K - More than dh-5 [42]
dhvar5 L L L - L L - K R K K - K - More than dh-5 [42]
P-113 A K R H H G Y K R K F H
113-F4.5.12 - - - F F - - - - - - F Similar to P-113 [34]
113-Y4.5.12 - - - Y Y - - - - - - Y Similar to P-113 [34]
113-L4.5.12 - - - L L - - - - - - L Less than P-113 [34]
113-Q2.10 - Q - - - - - - - Q - - Not active [34]
113-Q3.9 - - Q - - - - - Q - - - Less than P-113 [34]
113-Q2.3.9.10 - Q Q - - - - - Q Q - - Not active [34]
113-K6 - - - - - K - - - - - - Less than P-113 [34]
113-H8 - - - - - - - H - - - - Similar to P-113 [34]







 Similar overall effects from modifications were observed with the peptide fragment 
P-113 (residues 4 – 15 of Hst-5). Substitution of positively charged lysine (113-Q2.10) or 
arginine (113-Q3.9) residues or both (113-Q2.3.9.10) led to a significant reduction or 
complete loss of antifungal activity [34], indicating that the cationic nature of the peptide 
fragment is crucial for the antifungal activity. On the other hand, modifications that led to 
increased hydrophobicity (113-F4.5.12, 113-Y4.5.12, 113-L4.5.12) or amphipathicity 
(113-K6, K113-H8, K113-K6H8) had little to no effect on the antifungal activity. These 
modifications on the fragments show that while the charges of the residues play role in 
the antifungal activity, as observed with the full-length Hst-5, the amphipathicity and 
hydrophobicity do not significantly contribute to the activity. 
1.1.6. Proteolytic susceptibility to Saps 
 The antifungal properties of Hst-5 show its promise as a tool to fight C. albicans 
infection in the human mouth. However, the peptide can be cleaved and inactivated by 
the Saps produced by C. albicans. Meiller et al. showed that at physiological pH Hst-5 is 
vulnerable to proteolysis by Sap2, Sap9, and, to a lesser extent, Sap10 (Table 1.5) [20]. 
Furthermore, Bochenska et al. showed Hst-5 can also be cleaved by Sap1, Sap3 – 4, and 
Sap7 – 8 when tested at the optimal pH condition for each Sap [25]. The susceptibility of 
Hst-5 to proteolysis by the Saps motivates further study to explore whether reduction of 








Table 1.5. Fragments detected from cleavage by Sap1 – 4 and Sap7 – 10. 
Sap Ref.
1 4 8 12 16 20 24
D S H A K R H H G Y K R K F H E K H H S H R G Y
D S H A K R H H G Y K R K F H E K 1, 2, 3, 4, 9, 10 [20, 25]
H H S H R G Y 1, 2, 3, 4, 8, 9 [20, 25]
D S H A K R H H G Y K R K 2, 3, 9 [20, 25]
F H E K H H S H R G Y 2, 3, 7, 8, 9, 10 [20, 25]
D S H A K R H H G Y K R 2, 4, 7, 9 [20, 25]
D S H A K R H H G Y 2, 4, 8, 9 [20, 25]
R K F H E K H H S H R G Y 10 [20]
D S H A K 2 [20]
R H H G Y 2 [20]
K R K F H E K 1, 2 [20, 25]
H H S H R G Y 1, 2 [20, 25]
K F H E K 2 [20]
R H H G Y K R K 2 [20]
F H E K 1, 2, 3, 9 [20, 25]
A K R H H G Y K R K F H E K 1 [25]
A K R H H G Y 1 [25]
K R K F H E K 1 [25]
K R K F H E K H H S H R G Y 4 [25]
D S H A K R H H G Y K R K F H E K H H S H 7 [25]




1.2. Toward diagnostic improvements 
 Early detection of a fungal infection is strongly desirable to enable the identification 
and the start of appropriate treatments. For Candida infections, determination of the 
species causing the infection is important as some of the drugs are less effective in 
treating certain species than others [7] and the occurrence of drug-resistant strains is 
increasing [8]. The current gold standard for diagnosis of Candida infection is culturing 
of a clinical sample. However, this method is time-consuming, requiring 24 – 72 hours or 




infections are identified [43]. These current limitations in diagnostics show the need for 
and motivate further study into improving diagnostic methods. 
1.2.1. Antibody array and single-chain variable fragments (scFvs) 
 A potential alternative approach to diagnosis is to use an array of antibodies that will 
bind to the Candida cells and, based on the binding pattern, identify the species. There 
are various types of antibodies used in biological applications, with the Y-shaped 
immunoglobulin G (IgG) antibody being one of the most commonly used isotypes 
(Figure 1.4) [44]. However, the multiple disulfide-bonds present in the full-size antibody 
limit the methods of its production.  
 Instead of the full-size IgG, small antibody fragments have seen increasing use due to 
their ease of production in Escherichia coli [44]. The single-chain variable fragment 
(scFv) is one such fragment, composed of the variable light chain (VL) and variable 
heavy chain (VH) domains of the antigen-binding site of an IgG antibody connected by a 
flexible linker (Figure 1.4). scFvs are one of the smallest IgG fragments that retain an 
antigen-binding capability similar to the full-length antibody [45]. Typical scFvs are 26-
28 kDa in size, considerably smaller than the 150 kDa of IgGs [44]. The small size of 
scFvs allows for easy insertion of their encoding DNA sequences into plasmids and fast 
replication in E. coli [46]. The ease of production while maintaining antigen-specificity 
makes scFvs great tools for developing antibody arrays. These antibody arrays could be 
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Oriented immobilization without harsh chemicals can be achieved by taking advantage of 
the affinity of different biological components through bioaffinity immobilization. The 
interaction of Protein A and the Fc region of full-length antibodies is one of the common 
bioaffinity interactions used for immobilization [50, 51]. This approach, however, is not 
applicable to scFvs since they lack the Fc region. Fusion tags such as the hexahistidine 
(6XHis) tag can also be used for oriented immobilization onto surfaces modified with 
nickel-nitriloacetic acid (Ni-NTA) [52, 53]. Unfortunately, the affinity of the 6XHis tag 
to Ni-NTA is weak and reversible, with a dissociation constant of Kd = 10
-7 M [54].  
 As an alternative to the weak interaction of the 6XHis tag with Ni-NTA, the biotin-
streptavidin interaction, which is one of nature’s strongest non-covalent bonds 
(Kd = 10
-14 M) [55], can be used. This interaction has been previously used to 
successfully immobilize IgG antibodies and fragments, typically by attaching biotin in 
vitro to lysine residues through sulfo-NHS/EDC chemistry and immobilizing onto a 
streptavidin-functionalized surface [56]. As with the covalent immobilization with 
NHS/EDC, the addition of biotin through chemical modification does not lead to site-
specific, oriented immobilization. 
 E. coli cells produce biotin holoenzyme synthetases, also known as biotin ligases, 
which covalently attach biotin in vivo to a specific lysine residue of a native E. coli 
protein called the biotin carboxyl carrier protein (BCCP) (Figure 1.5A) [57]. Fusion of 
the 87-residue BCCP to other proteins allows biotinylation of the fusion proteins [57, 58], 
and the biotinylated proteins can then bind to streptavidin to immobilize proteins from a 
cell lysate [59, 60]. In addition to the full-length BCCP biotinylation sequence, a 15-
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expands on the Chapter 2 work to test effects of additional amino acid modifications and 
also gain insight into the kinetics of the degradation by Sap9. The second part of this 
dissertation (Chapter 4 – 5) describes a purification-free method to immobilize scFvs 
onto a surface as a potential method to produce antibody arrays. Chapter 4 describes the 
method and its capabilities and Chapter 5 looks to improve the method through use of 
peptide linkers. Finally, Chapter 6 describes summarizes the contributions of this thesis 








Chapter 2: Designing histatin 5 variants for reduced susceptibility 




 Candida albicans is a fungal species that is part of the normal human flora. It  
commonly colonizes mucosal surfaces, including  the oral cavity in over 35% of healthy 
people [1]. However, C. albicans is also an opportunistic pathogen, and, under conditions 
of immune system disruption, such as infection with the human immunodeficiency virus 
(HIV), it causes an array of infections, most notably oral candidiasis, which is also called 
oral thrush.  
 To help prevent infections by C. albicans and other organisms, the human oral saliva 
contains an arsenal of proteins and peptides [24]. One such peptide that fights against C. 
albicans is the antimicrobial peptide histatin 5 (Hst-5). It is one of twelve members of the 
histatin family of histidine-rich peptides secreted by salivary glands in the human mouth 
[26], with the 24-amino-acid Hst-5 having the strongest activity [26, 27]. As part of host 
innate immunity, Hst-5 has been proposed to play a crucial role in maintaining C. 
albicans at commensal levels in the oral cavity [20]. Reduced levels of Hst-5 have been 
reported in HIV-positive patients [30] and may contribute to their high susceptibility to 
oral thrush. Unlike some other common antimicrobial peptides, Hst-5 does not act on C. 
albicans cells by forming pores on the cell membrane [31]; instead, the peptide acts 





 Although Hst-5 has potent activity against C. albicans, the fungal pathogen produces 
a family of ten secreted aspartic acids (Saps), some of which can degrade and inactivate 
Hst-5. The Saps play a role in a number of cellular processes and attributes, including cell 
adhesion, cell integrity, and virulence [9]. While Sap1 to Sap8 are fully secreted to the 
extracellular environment, Sap9 and Sap10 remain attached to the cell wall via a 
glycosylphosphatidylinositol (GPI) anchor [9, 10]. Each Sap contains the two conserved 
aspartic acids characteristic of aspartic proteases, along with four conserved cysteine 
residues [14].  
 Although Sap9 is the most highly expressed Sap in strains isolated from patients with 
both oral and vaginal Candida infections [11], studies on the substrate specificity of the 
Saps have focused most extensively on Sap2. Sap2 has a broad specificity that includes 
immune host proteins, such as immunoglobulin A and lactoferrin, and antimicrobial 
peptides like Hst-5 [10, 19-21]. Recently, the interaction of Sap2 and other Saps with 
antimicrobial peptides, including Hst-5, has been more carefully studied [19-21]. Meiller 
et al. showed that at physiological pH Hst-5 is vulnerable to proteolysis by Sap2, Sap9, 
and, to a lesser extent, Sap10 [20]. Furthermore, Bochenska et al. showed Hst-5 can also 
be cleaved by Sap1, Sap3 – 4, and Sap7 – 8 when tested at the optimal pH condition for 
each Sap [25]. In both studies, a lysine residue was typically present on at least one side 
of the sites cleaved by the Saps. These results suggest Saps may target the lysine residues 
in the Hst-5 sequence, which is supported by previous sequence-specific studies that 
indicate Saps prefer hydrophobic residues or basic residues [17, 18, 22, 64].  
 To improve the understanding of the interaction between Hst-5 and Saps, we 




investigations have elucidated how modifications to the sequence of Hst-5 modulate 
antifungal activity [34, 36, 38, 39, 42, 65], the effect of modifications on degradation 
specifically by aspartic proteases has not yet been explored. The designed variants were 
evaluated for susceptibility to proteolysis by C. albicans Saps and for antifungal activity 
against C. albicans. Our results demonstrate that even a single amino acid modification is 
sufficient to significantly modulate the degradation of Hst-5 by the proteases or C. 
albicans cells, while maintaining antifungal potency. Based on these findings, designing 
peptides for reduced proteolysis could be a viable approach for engineering antimicrobial 
peptides with increased resistance to proteolysis and, thus, longer-lived antimicrobial 
potency. 
 
2.2. Materials and methods 
2.2.1. Peptides and enzymes 
 The parent Hst-5 peptide and the variants in Table 2.1 were synthesized by GenScript 
with a purity ≥95% and trifluoroacetic acid salt removal to hydrochloride. Purified Sap2 
and Sap9 were gifted by Dr. Bernhard Hube from Friedrich Schiller University, 
Germany. The Saps were produced in Pichia pastoris, as previously described [16], and 
Sap9 was produced without its GPI anchor [18]. The proteolytic activities of the Saps 
were confirmed using the EnzChek Protease Assay Kit (ThermoFisher Scientific). 
2.2.2. Proteolytic degradation of the peptides 
 To determine the extent of degradation of the peptides by the Saps, Hst-5 and the 




peptide and 3.13 g/mL or 6.25 g/mL protease for Sap9 or Sap2, respectively. 
Experiments were done in 1 mM NaPB. The mixtures were incubated at 37 °C for 2 h, 
and NaPB with no Sap was used as a control. After the incubation, the samples were 
mixed with tricine sample buffer (without Coomassie Blue G-250, except in control 
samples) containing β-mercaptoethanol and boiled for 5 min at 100 °C to inactivate the 
proteases. The degraded and non-degraded peptides were separated by gel electrophoresis 
in 10 – 20% Tris-tricine gels (Bio-Rad), and the gels were then fixed in a 10% acetic 
acid/40% methanol/50% water mixture for 30 min. The fixed gels were stained with Bio-
Safe Coomassie stain (Bio-Rad) for 1 h and washed with fresh water three times, once 
overnight and then twice for at least 2 h each time. The gels were imaged on a Chemidoc 
imager (Bio-Rad), and densitometric analysis was done with Image Lab software (Bio-
Rad). In the analysis, the upper band was taken as intact peptide and the lower band was 
taken as degraded products. Three replicates of the assay were done. 
 For degradation with C. albicans, a single colony of the ATCC 90028 strain 
(American Type Culture Collection) was used to inoculate YPD. The culture was grown 
overnight, subcultured, and grown to an optical density of 1 – 1.2 at OD600. All 
incubations were done at 30 °C. The cells were washed three times in 100 mM NaPB and 
diluted to 2×109 cells/mL. Equal volumes of cells and peptides were mixed and incubated 
for 2 h at 37 °C. The cells were removed by centrifugation, and the supernatants were 
mixed with tricine sample buffer and boiled for 10 min. The samples were then run on 
gels and analyzed as described above for degradation by the Saps. Three biological 




 For statistical analysis, we performed one-way ANOVA tests with p< 0.05 and 
Dunett’s multiple comparison tests with the Hst-5 sample as the control. The number of 
asterisks indicates the level of statistical significance: * for p< 0.05, ** for p< 0.01, *** 
for p< 0.001, and **** for p< 0.0001. 
2.2.3. Antifungal activity assay 
 The anti-Candida activities of the intact peptides were assessed by an antifungal 
activity assay. As described above for the degradation assay, an overnight culture of C. 
albicans was subcultured and grown in YPD media. Cells were washed three times in 
2 mM NaPB and diluted to 5×105 cells/mL or 5×107 cells/mL. Serial dilutions (0 –
 100 μM for the lower cell density and 0 – 400 μM for the higher cell density) of parent 
Hst-5 and the Hst-5 variants were prepared in water, and 20 L of the peptides and 20 L 
of the cells were mixed and incubated in round-bottom 96-well culture plates for 30 min 
at 30 °C. After incubation, 320 L of 1 mM NaPB was loaded into each well to stop 
additional killing of the cells by the peptides [66]. Mixtures were further diluted and 
approximately 250 cells were inoculated into round-bottom culture plates with equal 
volumes of YPD media and 1 mM NaPB at a total volume of 200 L. Wells containing 
only YPD and NaPB were served as a sterility control and provided measurements for the 
background signal. The OD600 was measured after overnight incubation on a microplate 
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 To measure the antifungal activity of the peptides following degradation by the Saps, 
the antifungal activity assay was performed as described above, except the peptides were 
first exposed to Saps. The peptide fragments were prepared by incubating each peptide 
(150 g/mL) with 6.25 g/mL Sap9 or 18 g/mL Sap2 for 2 h at 37 °C. The enzymes 
were then inactivated by heating at 100 °C for 5 min. As controls, each peptide was also 
incubated with only NaPB buffer. Samples were then stored at –20 °C until use in the 
antifungal activity assay. 
2.2.4. MS/MS analysis 
 The cleavage sites of the Saps and the abundance of the fragments produced by 
cleavage were determined using mass spectrometry. After incubation with 3.13 g/mL 
Sap9 or 6.25 g/mL Sap2 and heat inactivation of the Saps, 25 L of each sample was 
desalted using a C-18 TopTip micro-spin column (Glygen Corp.) following the 
manufacturer’s protocol. The binding solution was 0.1% formic acid, and the releasing 
solution was 0.1% formic acid/60% acetonitrile (ACN). To ensure equal flow-through 
volume of each sample, 18 L of desalted sample was aliquoted and 1 L of the four-
amino acid peptide MRFA at 0.1 mg/mL was added. Samples were manually loaded 
through loop injection at 25 L/min with 40% ACN/0.1% formic acid. Mass spectra were 
acquired with a Thermo Scientific Orbitrap Fusion Lumos Tribrid mass spectrometer 
with data-dependent analysis at a 5 s cycle time. Manufacturer recommended source 
parameters for a flow rate of 25 L/min were applied. Full scan mass spectra of m/z 
350 – 1550 were acquired in the orbitrap at R=120000 (m/z 200) with fluoranthene ion as 
the internal calibrant. CID and ETD fragments of the most intense ions (z> 1) were 




 The molecular weights of the peptides and their fragments were calculated from full 
scan MS spectra using the XTract program in the XCalibur software (Thermo Scientific). 
MS/MS spectra from electron-transfer dissociation (ETD) and collision-induced 
dissociation (CID) fragmentation were processed using Proteome Discoverer (V2.1) with 
Prosight PD node to identify peptides and their degradation products (Figure A.1). The 
database was the collection of Hst-5 and its analogs used in this study. Intensities of 
identified peptides and their degradation products relative to the internal standard MRFA 
were obtained from the deconvoluted full scan mass spectra (Figure A.2). 
 
2.3. Results and discussion 
 To study the interaction of Hst-5 with C. albicans Saps, we evaluated the proteolysis 
of Hst-5 and eight variants by Sap2 and Sap9, which substantially cleaved Hst-5 in 
previous work from Meiller et al. [20]. Our design of the Hst-5 variants focused on the 
four lysine residues in the peptide, as we observed that lysine residues are prominent at 
the reported cleavage sites of Hst-5 with Saps or C. albicans cells [20, 25]. We 
hypothesized that these lysine residues are important for the recognition or cleavage of 
Hst-5 and replaced each of the lysine residues with either an arginine or a leucine (Table 
2.1). The arginine substitutions were selected to preserve the positive charge, as the 
cationic nature of antimicrobial peptides often plays a role in their function [67, 68]. The 
leucine substitutions were selected to remove the positive charge, which could affect the 






Table 2.1.Variants of Hst-5 with arginine or leucine substitutions at lysine residues.  
Peptide Sequencea 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y
K5R - - - - R - - - - - - - - - - - - - - - - - - - 
K5L - - - - L - - - - - - - - - - - - - - - - - - - 
K11R - - - - - - - - - - R - - - - - - - - - - - - - 
K11L - - - - - - - - - - L - - - - - - - - - - - - - 
K13R - - - - - - - - - - - - R - - - - - - - - - - - 
K13L - - - - - - - - - - - - L - - - - - - - - - - - 
K17R - - - - - - - - - - - - - - - - R - - - - - - - 
K17L - - - - - - - - - - - - - - - - L - - - - - - - 
a Dash indicates residue was unchanged from the parent Hst-5. 
 
2.3.1. Lysine substitutions modulate susceptibility to proteolysis by purified Saps 
 To determine whether the single-residue substitutions have an effect on the overall 
degradation of Hst-5, we incubated Hst-5 and each modified peptide with purified 
recombinant Sap9 and Sap2. Hst-5 and each variant in Table 2.1 were incubated with or 
without 3.13 g/mL Sap9 or 6.25 g/mL Sap2 for 2 h at 37 °C in 1 mM sodium 
phosphate buffer (NaPB). We then separated the intact peptide from the degradation 
products using gel electrophoresis and quantified the level of degradation using 
densitometric analysis of Coomassie-stained gels (Figure 2.1). Both arginine and leucine 
substitutions at the K17 site led to a dramatic decrease in degradation by Sap9 and Sap2. 
Following incubation with Sap9, 82% and 77% of K17R and K17L, respectively, 
remained intact compared to 47% of Hst-5 (Figure 2.1A). No detectable degradation of 
the K17R and K17L variants was visible after incubation with Sap2, while only 61% of 
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 These results demonstrate the ability to easily detect changes in a peptide’s 
susceptibility to proteolysis by gel electrophoresis and indicate that this approach is 
feasible for exploring how aspartic proteases interact with antimicrobial peptides. 
Additionally, they demonstrate that single-residue changes can have a major impact on 
the susceptibility of a peptide to degradation by Saps. 
2.3.2. Proteolysis by C. albicans cells is comparable to proteolysis by purified Saps 
 After observing the effect of residue modifications on the cleavage of Hst-5 by the 
purified recombinant Saps, we evaluated whether incubation of the peptides with whole 
C. albicans cells natively expressing Saps (rather than with Saps produced 
recombinantly) would yield similar results. Hst-5 and the variants were incubated with 
C. albicans cells for 2 h at 37 °C in 100 mM NaPB. The high ionic strength of this buffer 
prevents internalization of the peptides by C. albicans [69], allowing analysis of 
degradation of the peptides without the confounding effects of peptide internalization, 
which would reduce the amount of peptide available for degradation by the Saps in the 
buffer. Following incubation with the cells, the peptide samples were run on a gel and 
stained, and densitometric analysis revealed a pattern that exhibits characteristics of the 
results observed with the individual Saps (Figure 2.2). As seen with the results for 
purified Sap9 and Sap2, both K17 modifications resulted in an increase in the amount of 
intact peptide remaining. The results for the K13L peptide followed the Sap9 proteolysis 
pattern, with an increase in degradation compared to the parent Hst-5. The peptides with 
modifications at K5 showed a mixed pattern, with a decrease in proteolysis for K5L 
emulating the Sap2 result and no significant effect for K5R emulating the Sap9 result. 
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the peptides with each Sap, the four-amino-acid peptide MRFA was added as an internal 
standard, and samples were directly injected into the mass spectrometer.  
 Mass spectrometry of the parent Hst-5 peptide incubated with Sap9 showed that the 
signal for the degradation fragment containing amino acids 1 – 17 of Hst-5 was higher 
than the intact peptide (Figure 2.3). We observed cleavage on both sides of K13 and on 
the C-terminal side of K17, which are cleavage sites that have been previously reported 
for Sap9 and Sap2 [20, 25]. No cleavage was seen on either side of the K11 residue, 
consistent with the work of Bochenska et al. [25], though Meiller et al. did report 
cleavage at the N-terminal side of this residue [20]. We also detected cleavage between 
the H18 and H19 residues of the parent Hst-5, which has previously been observed after 
incubation with C. albicans cells [70] but not specifically associated with Sap9. 
 In general, the degradation of the Hst-5 variants with Sap9 produced results in 
agreement with the gel electrophoresis data. For K17R and K17L, the most intense signal 
came from the intact peptide, as expected from the large percentage of intact peptide seen 
in the gel electrophoresis results (Figure 2.1A). Furthermore, while the parent Hst-5 was 
cleaved on the C-terminal side of K17, neither K17R nor K17L showed significant 
cleavage at this site. K11R also shows the intact peptide to be the species with the highest 
signal. With the exception of the peptides with K17 substitutions, the variants with 
leucine substitutions showed relatively lower levels of intact peptide than the 
corresponding arginine-substituted peptides. Furthermore, K13L showed an apparent 
shift in cleavage site preference compared to the parent Hst-5. The fragments containing 
amino acids 1 – 12 and 13 – 24 had higher signals for K13L than the fragments 
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for the other modified peptides and parent Hst-5. The loss of cleavage site for the K17-
modified peptides and the shift in cleavage site preference for K13L show that the 
substitutions affect cleavage around the modified residues. In addition, the presence of 
more intact peptide for K11R indicates that substitutions can also affect the peptides as a 
whole. 
 In contrast to incubation with Sap9, incubation of the parent Hst-5 peptide with Sap2 
resulted in the intact peptide having the highest signal under the conditions tested (Figure 
2.4). A lower number of distinct fragments was detected for Hst-5 degradation by Sap2 
compared to Sap9. For example, the fragments containing amino acids 1 – 12 and 13 – 24 
were not significantly detected in incubation with Sap2 but were detected with Sap9. The 
cleavage sites that did occur with Sap2 were also observed with Sap9 and are in 
agreement with previously reported results [20, 25], except that cleavage between H18 
and H19 was not previously specifically attributed to Sap2. Meiller et al. also reported a 
cleavage site at the C-terminal side of K5 [20], which neither we nor Bochenska et al. 
observed [25]. 
 As with incubation of the parent Hst-5, incubation of all the Hst-5 variants with Sap2 
resulted in higher signals for intact peptides than for proteolytic fragments. The outcome 
was in line with the gel electrophoresis result, which showed that, overall, the Hst-5 
variants incubated with Sap2 had more intact peptide remaining than when incubated 
with Sap9 (Figure 2.1). Substitutions at K17 did lead to a significant decrease in signals 
from fragments formed by cleavage at the C-terminal side of K17; however, unlike Sap9, 
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Unlike Sap9, Sap2 still cleaved at the C-terminal side of K17, suggesting the preference 
is more stringent for Sap9 than Sap2. At the other locations where lysine residues were 
modified, Sap9 appears to favor an uncharged leucine over a positively charged arginine 
or lysine. The leucine residues at these sites are N- or C-terminal to an arginine in the 
peptide sequence, and their preference by Sap9 agrees with previous work indicating 
Sap9 favors cleavage of peptides that contain leucine at the N-terminal side of an arginine 
[18]. Sap2, on the other hand, appears to favor lysine at the residues of Hst-5 that we 
studied. The preference is residue-dependent rather than charge-dependent, as Sap2 
preferred lysine over both arginine and leucine. The one exception was at the K13 site, 
where Sap2 appears to prefer an arginine. Collectively, these results confirm our gel 
electrophoresis results and indicate single amino-acid modifications can affect overall 
susceptibility to cleavage and significantly reduce cleavage at the modification site. 
2.3.4. Most residue substitutions do not diminish antifungal activity 
 Some previously reported modifications to Hst-5 had a negative impact on the 
peptide’s antifungal activity [36, 38, 39]. To ensure that modification of lysine residues 
does not adversely affect the antifungal activity, we performed an antifungal activity 
assay to determine the reduction in the viability of C. albicans cells after exposure to the 
parent Hst-5 peptide and the Hst-5 variants (Figure 2.5). Serially diluted peptides were 
incubated with C. albicans cells at 2.5×105 cells/mL or 2.5×107 cells/mL C. albicans for 
30 min at 30 °C in 1 mM NaPB. The mixtures were then diluted, transferred to YPD 
media, and incubated overnight to determine the reduction in cell viability due to 
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fragments for antifungal activity—fragment C14 (residues 11 – 24) [33] and fragment P-
113 (residues 4 – 15) [34]. Therefore, the K11R modification is at a critical location in 
the peptide and altering the interaction of the peptide with the Saps at this residue could 
have a larger effect on the antimicrobial activity of the peptide and its degradation 
fragments than most other lysine residues. Interestingly, neither K17R nor K17L showed 
improvement in antifungal activity despite the gel and mass spectrometry results that 
demonstrated more intact peptide. This may be a function of the incubation time in the 
assay. The antifungal assay we used (based on the assay used by several other groups [34, 
39, 66]) incorporates a short contact time for the peptides and C. albicans to minimize the 
effect of cell division on assay results. Since the kinetics of proteolysis of the in vivo Saps 
may be slow enough that their effect on Hst-5 is not easily observed under these 
conditions, improvements of the K17 modifications on antifungal activity may not be 
observed at the conditions tested. Overall, the antifungal activity assay demonstrates that 
replacement of a lysine with an arginine or a leucine does not abolish the antifungal 
activity of the Hst-5 and may lead to improvements. While there have been no previous 
studies evaluating the effect of lysine to arginine modifications on the antifungal activity 
of Hst-5, Helmerhorst et al. reported that a lysine to leucine substitution in a fragment of 
Hst-5 called dh-5 showed similar activity to the peptide containing lysine [35], further 
supporting the tolerance of Hst-5 to lysine-to-leucine modifications. 
2.3.5. Several Hst-5 variants retain antifungal activity after treatment with Saps 
 After confirming that substitutions to the lysine residues did not eliminate antifungal 
activity, we investigated whether the peptides retained their antifungal activity after 
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 Overall, following degradation by each of the Saps, the arginine-substituted peptides 
retained more antifungal activity compared to the analogous leucine-substituted peptides. 
For example, the Sap9- and Sap2-degraded K5R and K11R variants still displayed some 
antifungal activity, while the degraded K5L and K11L variants showed almost none. The 
K5R and K11R peptide also retained some intact peptide after Sap9 incubation (4.5% and 
20% of peptide, respectively), while no statistically significant amount of these peptides 
remained after Sap2 incubation (Figure 2.7B). The presence of intact K5R and K11R but 
not intact K5L and K11L after incubation with Sap9 further supports a preference for 
leucine at these sites by Sap9 and also shows a preference for lysine over arginine, since 
the parent Hst-5 is completely degraded under these conditions.   
 Although the variants with the largest amount of intact peptide remaining had the 
strongest antifungal activity, intact peptide was not required for antifungal activity. The 
parent Hst-5 peptide had no intact peptide remaining after incubation with Sap9, but it 
did show a measurable level of antifungal activity. Moreover, while less intact K11R 
peptide remained after incubation with Sap9 compared to K17R or K17L (Figure 2.7A), 
the antifungal activity was at the same level as the K17 modified peptides. This suggests 
that the antifungal activity comes not only from the intact K11R peptide, but also from its 
proteolytic fragments. This is consistent with previous studies with Hst-5 that found 
varying levels of antifungal activity from Hst-5 truncation peptides [33-35]. 
 Our results indicate that, while some peptide modifications make the intact peptide 
more robust (e.g., K17R, K17L), others can lead to degradation fragments with improved 
antifungal activity compared to the degradation fragments of parent Hst-5 (e.g., K11R). 




antifungal activity themselves, a longer half-life of intact peptide or a higher activity of 
degradation fragments leads to improved therapeutic potential of K11R, K17R, and K17L 
compared to Hst-5. We recently showed that Hst-5 delivered in a bioadhesive hydrogel 
could effectively prevent the development of an oral C. albicans infection in mice [71]. 
The modified peptides could be delivered directly to mucosal surfaces in the same 
manner, or they could be incorporated into coatings on implantable devices or prosthetics 
using thin films, which have been used previously to successfully create antimicrobial 
surfaces using other antimicrobial peptides [72-74]. 
 
2.4. Conclusion 
 We have demonstrated that changing a single lysine residue in the Hst-5 sequence can 
significantly alter its proteolysis by purified Sap9 and Sap2, as well as by whole C. 
albicans cells. Further, we show that the effects of the modifications are site-, residue-, or 
Sap-dependent, and the substitutions affect not only cleavage at the substitution sites but 
also the degradation of the peptide as a whole. These findings can be used to design and 
test additional modifications to study the interaction between Hst-5 and both Saps and 
C. albicans cells. Additionally, our work provides peptide engineering approaches that 
can be used to design more robust peptides in the presence of aspartic proteases, which 




Chapter 3: Effects of histatin 5 residue modifications on kinetics of 




 Chapter 2 demonstrated that substitutions of single lysine in histatin 5 (Hst-5) to 
arginine or leucine have site-, residue-, and protease-specific effects on the antifungal 
peptide’s susceptibility to proteolysis by secreted aspartic proteases (Saps), produced by 
Candida albicans. Furthermore, the substitutions do not diminish the antifungal activity 
of the peptide. The study found modifications that enhanced the resistance to degradation 
by Sap9, Sap2, and C. albicans cells (K17R and K17L), as well as a modification that 
enhanced the antifungal activity (K11R). The K17R and K17L peptides also retained 
significantly higher antifungal activity than Hst-5 after exposure to Saps. However, not 
all of the tested lysine substitutions led to enhanced properties. In fact, the K13 site 
modifications led to an increase in susceptibility to proteolysis by Sap9 and C. albicans 
cells. Interestingly, while the K13L modified peptide was particularly susceptible to 
Sap9, it maintained antifungal activity similar to Hst-5. 
 To gain further insight into interactions between Hst-5 and C. albicans, this chapter 
expands on the study in Chapter 2 by investigating additional amino acid modifications at 
the K13 and E16 residues and combining two previously tested lysine modifications. The 
effects of the substitutions on the susceptibility to proteolysis by Saps and C. albicans 
and on the antifungal activity were tested. A time course study on the proteolysis of Hst-5 




kinetics. The study revealed that residue substitution significantly affected the kinetics of 
proteolysis and modifications that make the overall peptide more susceptible to 
degradation could lead to fragments with enhanced antifungal activity. It also 
demonstrated the effects from single amino acid modifications can be combined into one 
peptide, which expands the possibilities of future designs of antimicrobial peptides.  
 
3.2. Materials and methods 
3.2.1. Peptides and enzymes 
 Hst-5 and its variants were synthesized by Genscript (purity ≥95% with 
trifluoroacetic acid salt removal to hydrochloride). Dr. Bernhard Hube from Friedrich 
Schiller University, Germany provided the recombinant Sap2 and Sap9. The Saps were 
expressed in Pichia pastoris [16], and Sap9 was expressed sans its GPI anchor [18]. 
 
3.2.2. Degradation of peptides by Saps and C. albicans 
 The overall extent of proteolysis of the peptides by purified Saps was evaluated 
through gel electrophoresis. Hst-5 and its variants (20 μL) were mixed with Saps (20 μL) 
in 0.5 mL microcentrifuge tubes to final concentrations of 50 μM peptide and 3 μg/mL 
Sap9 or 0.05 μg/mL Sap2. As controls, the peptides were mixed with sodium phosphate 
buffer (NaPB). The incubations were done in 1 mM NaPB for 2 h at 37 °C. The samples 
were then mixed with tricine sample buffer (200 mM Tris-HCl, pH 6.8, 40% glycerol, 
2% SDS, no Coomassie Blue G-250) containing 2% β-mercaptoethanol and heated at 




products, the samples were run on 16.5% Tris-tricine gels (Bio-Rad) at 60 V. After 
separation, the gels were fixed for 30 min in a 10% acetic acid/40% methanol/50% water 
fixing solution and stained with Bio-Safe Coomassie stain (Bio-Rad) for 1 h. The stained 
gels were washed with fresh water four times: once overnight and at least 1.5 h each for 
the rest of the washes. The stained gels were imaged on a Chemidoc imager (Bio-Rad). 
Image Lab software (Bio-rad) was used for densitometric analysis, where the upper band 
in each lane was analyzed as non-degraded peptide and the lower band was analyzed as 
degraded products. Degradation reactions were performed on three different days with 
two replicates with in each day for total of n = 6.   
 For the study of proteolysis by C. albicans, an overnight culture of the ATCC 90028 
strain (American Type Culture Collection) was subcultured and grown in YPD media 
(10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose) at 30 °C to an optical density 
(OD600) of 1 – 1.2. Cells were harvested and washed three times in 100 mM NaPB. 
Washed cells were resuspended in the buffer and mixed with an equal volume of each 
peptide to final concentrations of 1×109 cells/mL C. albicans and 50 μM peptide. As 
controls, the peptides were mixed with NaPB. After incubation for 2 h at 37 °C, cells 
were removed by centrifugation and heated at 100 °C for 10 min after addition of tricine 
sample buffer. Afterwards, following the protocol described above for degradation by 
Saps, samples were run on Tris-tricine gels, stained, and analyzed. Degradation reactions 
were performed on three different days with two replicates with in each day for total of 
n = 6.   
 One-way ANOVA tests with p< 0.05 and Dunett’s multiple comparison tests (Hst-5 




significance in figures is indicated by the number of asterisks: * for p< 0.05, ** for p< 
0.01, *** for p< 0.001, and **** for p< 0.0001. 
3.2.3. Capillary electrophoresis-mass spectrometry 
 Capillary electrophoresis-mass spectrometry (CEMS) was used to determine and 
quantify the fragments formed from cleavage by Saps. Once Saps (3 μg/mL Sap9 or 0.05 
μg/mL Sap2) were heat inactivated after incubation with 50 μM peptides, 25 μL of each 
sample was desalted with a C-18 TopTip micro-spin column (Glygen Corp.) following 
the manufacturer’s protocol. Solutions of 0.1% formic acid and 0.1% formic acid/60% 
acetonitrile (ACN) were used for binding and eluting, respectively. To each elution, 1 μL 
of the peptide MRFA (0.1 mg/mL) was added as an internal standard. The samples were 
further diluted with 0.1% formic acid before CEMS analysis. 
 The separation was done at 30 kV with a CMP Scientific ECE-001 capillary 
electrophoresis system with a CMP Scientific EMASS-II ion source. An etched capillary 
with PS1 neutral coating was used with the system.  
 A Thermo Scientific Orbitrap Fusion Lumos Tribrid mass spectrometer was used to 
acquire full mass spectra in the range of 200 – 1450 m/z with resolution R=120000 (200 
m/z). EthcD spectra at R=120000 (200 m/z) with a 3 s cycle time were recorded to 
identify peptide fragments from degradation by Saps. The EthcD spectra of each sample 
were processed with Proteome Discoverer (V2.1) with the Prosight PD node to identify 
the degradation products. Full scan mass spectra were deconvoluted, and the intensities of 
the intact peptide, fragments, and the internal standard MRFA were analyzed with 




3.2.4. Kinetics of proteolysis 
 To gain an understanding of the kinetics of the interaction between the peptides and 
Saps, a time-course study on the proteolysis of Hst-5 and its variants by Sap9 was 
performed. As described for the proteolytic study with gel electrophoresis, a series of 
peptide and Sap9 mixtures with final concentrations of 50 μM peptide and 3 μg/mL Sap9 
were prepared. Samples were incubated for 5 min, 30 min, or 120 min at 37 °C and then 
heated at 100 °C for 5 min to inactivate Sap9. For the 0 min time point, Sap9 was first 
heat inactivated and then added to the peptides. The samples were desalted with a C-18 
TopTip micro-spin column and analyzed by CEMS as described above. 
3.2.5. Antifungal activity assay with intact peptide and fragments 
 The antifungal activity of intact parent Hst-5 and its variants was evaluated using an 
optical density-based candidacidal assay. An overnight culture C. albicans was 
subcultured and grown at 30 °C in YPD media to an OD600 of 1 – 1.2. Cells were 
harvested, washed three times with 2 mM NaPB, and diluted to 5×107 cells/mL. 
Meanwhile, each of the peptides was serially diluted (0 – 400 μM) in water. Equal 
volumes (20 μL) of diluted cells and diluted peptide were then mixed in a round-bottom 
96-well culture plate. As a control, an equal volume of water was mixed with the diluted 
cells. After 30 min of incubation at 30 °C, 320 μL of 1 mM NaPB was added to stop 
additional interaction of peptides and cells [66]. Samples were further diluted and 
approximately 250 cells were inoculated into an equal mixture of YPD (100 μL) and 
1 mM NaPB (100 μL) in round-bottom culture plates, and the cells were grown overnight 




background signal. After overnight incubation, cells in each well were resuspended, and 
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The activity assays were performed on three different days with two replicates with in 
each day for total of n = 6.   
 For determining the antifungal activity of the peptides after exposure to Saps, 50 μM 
peptide was first incubated with 6 μg/mL Sap9 or 0.2 μg/mL Sap2 for 2 h at 37 °C. After 
the incubation, the Saps were inactivated by heating the samples at 100 °C for 5 min. As 
controls, the peptides were mixed with NaPB. The antifungal activity of Sap-incubated  
samples was assessed following the described protocol for intact peptide, with the 
modification of using a lower C. albicans concentration of 5×105 cells/mL. Degraded 
peptide samples were prepared on two different days for each of the Saps. The antifungal 
activity assays were performed on two different days for each Sap samples with two 
replicates within the same day for total of n = 4.  
 
3.3. Results  
 To further characterize the interaction between Hst-5 and C. albicans, new residue 
modifications to the Hst-5 sequence were designed and tested (Table 3.1). The 
investigation of the K13 site was continued as at it is part of both antifungal fragments of 
Hst-5 (residues 4 – 15 [33] and 11 – 24 [34]). Histidine was substituted at the K13 site to 
form an arginine-histidine pair with the R12 site since no prior cleavage between 




reported [20]. Bocheska et al. did report cleavage with Sap7, but it was in buffer and pH 
conditions optimal for Sap7. The K13E modified peptide was also designed to test the 
potential role of negative charge in proteolysis at the site. Although the K13E substitution 
has been previously tested for its impact on antifungal activity [38], its effect on 
proteolysis has not been explored.  
 
Table 3.1. Hst-5 and variants with one or two amino acid substitutions.  
Peptide
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y
K13H - - - - - - - - - - - - H - - - - - - - - - - -
K13E - - - - - - - - - - - - E - - - - - - - - - - -
E16R - - - - - - - - - - - - - - - R - - - - - - - -
E16L - - - - - - - - - - - - - - - L - - - - - - - -
K11R-K17R - - - - - - - - - - R - - - - - R - - - - - - -
Sequencea
 
a Dash indicates residue was unchanged from the parent Hst-5. 
 
 
 A new substitution at the E16 site was investigated since the glutamic acid at the site 
is the only negative-charged residue in the active fragments of the peptide. It is also next 
to the K17 site where the modifications to arginine and leucine enhanced the peptide’s 
resistance to Saps. To test the role of the negative charge on the robustness and the 
activity of Hst-5, it was modified to a positively charged arginine or an uncharged 
leucine.  
 Finally, to determine whether the enhancements seen with single amino acid 
modifications (Chapter 2) can be combined to achieve further enhancement, both K11 




antifungal activity and the K17R modification led to enhanced resistance to proteolysis, 
the new peptide was hypothesized to have both of the enhanced properties. 
3.3.1. Modified peptides are more susceptible to Sap9 
 The effect of the amino acid modifications on the overall proteolytic susceptibility of 
Hst-5 was evaluated by incubating Hst-5 and its variants with purified, recombinant Sap9 
and Sap2. After 2 h of incubation at 37 °C in 1 mM NaPB, the intact peptide and 
degradation products were separated via gel electrophoresis. The level of degradation was 
quantified through densitometric analysis of Coomassie-stained gels (Figure 3.1). The 
double substituted peptide K11R-K17R showed significantly enhanced resistance to both 
Saps. Compared to 37% of parent Hst-5, over 88% of intact K11R-K17R peptide 
remained after incubation with Sap9 (Figure 3.1A). The modified peptide’s resistance to 
proteolysis was even greater for Sap2; no detectable level of the K11R-K17R degradation 
was observed whereas only 37% of intact Hst-5 remained (Figure 3.1B).   
 Overall, the modified peptides were more susceptible to degradation by Sap9 than 
Sap2. The E16R modification enhanced resistance to Sap2, with 60% of intact peptide 
remaining (Figure 3.1B). However, there was significantly more degradation when 
exposed to Sap9 (Figure 3.1A). A similar pattern was also observed at the K13 site. After 
exposure to Sap2, the K13H and K13E peptides retained an amount of intact peptide 
comparable to Hst-5, but they were completely degraded by Sap9. It should be noted that 
the source of the additional band in the K13H lane that is at a molecular weight higher 
than intact peptide  is currently unknown and was not considered in the analysis (Figure 
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3.3.2. Proteolysis by C. albicans follows the degradation pattern for Sap9 and Sap2 
 To determine the proteolytic effect when the peptides are exposed to natively 
expressed Saps, the peptides were incubated with C. albicans. The parent Hst-5 and the 
modified peptides were incubated with C. albicans for 2 h at 37 °C in 100 mM NaPB (the 
high ionic buffer was used to prevent internalization of the peptides into the cells [69]). 
The cells were removed by centrifugation and the peptides were run on a gel. The extent 
of degradation was quantified via densitometric analysis of the stained gels (Figure 3.2). 
As expected from the recombinant Sap results, the K11R-K17R modified peptide showed 
a significant increase in resistance to proteolysis by C. albicans, with over 81% of intact 
peptide remaining compared to 54% of Hst-5. The degradation of the K13-modified 
peptides mimicked the results with recombinant Sap2 more closely than the results with 
recombinant Sap9. The amount of intact K13H peptide remaining was comparable to 
Hst-5, and, although the K13E peptide had less intact peptide, it still retained more full-
length peptide than the E16L peptide, as observed after incubation with Sap2. On the 
other hand, the proteolysis of the E16R peptide more closely resembled the Sap9 result; 
less intact E16R remained than intact Hst-5. However, despite the higher degradation of 
the E16R, the pattern of higher susceptibility of leucine-substituted peptides over 
arginine-substituted peptides for proteolysis was maintained (13% vs. 27% intact E16L 
and E16R, respectively). Other Saps are present when testing with whole C. albicans 
cells, and, therefore, some of the degradation may be due to Saps other than Sap2 or 
Sap9. This could account for the fact that the difference in intact peptide between Hst-5 
and the K11R-K17R modified peptide is smaller than when tested with Sap9 and Sap2 
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(Figure B.1). However, below a peak area of 1106, the signal to concentration 
relationship was found to be non-linear; therefore these values were not considered in the 
analysis. 
 For the relative abundance of intact peptide, the mass spectrometry results are 
consistent with the gel electrophoresis results for both Saps. The most abundant peptide 
in the E16R incubation with Sap2 and the K11R-K17R incubation with Sap9 and Sap2 
was the intact peptide (Figure 3.3). The same samples showed enhanced resistance to 
proteolysis in analysis by gel electrophoresis. For the rest of the peptide and Sap 
combinations, the fragment containing residues 1 – 17 was more prevalent than the intact 
peptide. The high abundance of the same fragment was also previously observed with 
single a lysine substitution at the K5 or K11 sites [75]. 
 Incubation with Sap9 led to significant degradation of E16R and E16L. While 
multiple different fragments were detected in the Hst-5 sample, only a few fragments 
remained in E16R and E16L samples, with little to no intact peptide (Figure 3.3A). The 
substantially lower amount of E16R peptide was surprising, as its presence was expected 
from the gel electrophoresis analysis (Figure 3.1A). The CEMS may not get a high signal 
from the intact E16R. Even in the sample incubated with Sap2, the signal of the intact 
E16R is lower than or comparable to the degradation fragments of other peptides 
 The mass spectra of the K11R-K17R peptide were quite different from Hst-5 or the 
other variants. First, no significant amount of the amino acids 1 – 17 fragment was 
detected after incubation with either Sap. This indicates that no cleavage occurred at the 
R17 site, as predicted during the peptide design, since the K17R substitution previously 
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3.3.4. Modifications modulate the rate of proteolysis by Sap9 
 The mass spectrometry analysis showed that residue substitutions change the type and 
abundance of the peptide fragments that remain after incubation for 2 h with Sap9, so a 
time-course study was conducted to characterize the kinetics of proteolysis by Sap9. The 
peptides Hst-5, E16L, and K11R-K17R were incubated with Sap9 for 5 min, 30 min, and 
120 min and analyzed with CEMS. For controls at 0 min, Sap9 that was first heat 
inactivated was added to the peptide samples.  
 Each of the tested peptides showed a unique degradation pattern (Figure 3.4).  For the 
intact peptides, Hst-5 and E13L were degraded at faster rate than K11R-K17R in the first 
5 min of incubation. The degradation rates of all the peptides slowed after 30 min of 
incubation and while some intact Hst-5 and K11R-K17R remained after 120 min, K13L 
was completely degraded. The formation and the degradation of the peptide fragments 
also showed variability among the peptides. For Hst-5, with the exception of the amino 
acids 3 – 17 and 7 – 24 fragments, the proteolytic fragments accumulated at increased 
rates after 30 min. On the other hand, most of the fragments of the E13L peptide, 
particularly the amino acids 1 – 17 fragment, accumulated during the first 30 min of 
incubation, but were subsequently degraded.  This could explain why only few fragments 
were detected in the data for the 120 min incubation (Figure 3.3). The presence of the 
residues 13 – 24 fragment, which has been seen with proteolysis by Sap9 but not Sap2 
(Figure 3.3), was also detected in middle of the time-course for K13L. Lastly, some of 
the fragments of the K11R-K17R peptide showed an interesting trend. The smaller 
fragments (amino acids 14 – 24 and 13 – 24), and N-terminus fragments (amino acids 1 – 
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nearly steady-state level. This suggests that these fragments are less preferred by Sap9 
once other fragments are formed in the first 30 min. The time-course study shows that the 
modifications to the peptides not only affected the rate of degradation of the intact 
peptide, but also the fragments formed from the degradation.  
3.3.5. Some amino acid substitutions lead to enhanced antifungal activity 
 Previous work demonstrated that substitution of a single lysine residue to arginine or 
leucine at the K5, K11, K13, or K17 sites in Hst-5 does not diminish the antifungal 
activity of the peptide, even if the modifications lead to an increase in proteolysis by Saps 
(Chapter 2). Therefore, all of the current Hst-5 variants were tested for their antifungal 
activity, even if the substitution led to an increase in the susceptibility to proteolysis. To 
determine the antifungal activity of Hst-5 and the modified peptides, the peptides were 
serially diluted and incubated with C. albicans cells at 2.5×107 cells/mL for 30 min at 
30 °C in 1 mM NaPB. The mixtures were then diluted, inoculated into YPD media, and 
grown overnight to determine the reduction in cell viability due to exposure to the 
peptides.  
 As hypothesized during the peptide design, the K11R-K17R modification led to 
enhanced antifungal activity (Figure 3.5) with a minimum inhibitory concentration for 
50% inhibition of growth (MIC50) of 25 μM. This improvement is comparable to the 
enhanced activity of the K11R modified peptide previously observed (Figure 2.5). 
Therefore, the enhanced antifungal activity of the K11R modification is preserved in the 





















































 not have a





at the K13 
e parent H
 Even at 20




































 the mean (n
tion for 50%
 led to enh
tion by C. 
ragment of 
e likely to 
 after incu








s for 30 min












ic to only a
sidue withi
tides (50 μM
 at 30 °C in






















































**** for p< 0






































































des (50 μM) 





















ror of the m
d by the num
le addition 











 (6 μg/mL S
ere run on a
s quantified
ts (lower ba


























































uffer for 2 h 
/mL C. albic









tivity of the 
0 μM) were i
at 37 °C. The
ans for 30 m
 (n = 4).  
58 
ctivity at a 
gel electrop
 intact K11R
















ns of the Sa
r incubation
h Sap9 (6 μg
re then serial
 1 mM NaP





ty of the E
-substituted
ps (Figure 
 with or with
/mL), Sap2 (
ly diluted an





























retained a high amount of antifungal activity. Interestingly, for the peptides that were 
incubated with Sap9, the fragments of the E16L peptide have greater antifungal activity 
than the fragments of the E16R peptide at higher equivalent peptide concentrations 
(Figure 3.7A). This could indicate that the E16L sample had more active fragments 
remaining than the E16R sample after exposure to Sap9. The perseverance of the 
fragments is particularly noticeable in the Sap2 incubated samples. After incubation with 
Sap2, essentially all of the antifungal activity of Hst-5 has been eliminated, but the E16-
modified peptides still retain a significant amount of activity. The antifungal activity 
assay further supports the notion that the substitution of glutamic acid with arginine and 




 This work explored effects of single amino acid substitutions and combination of 
previously studied lysine substitutions on Hst-5’s susceptibility to proteolysis by Saps 
and C. albicans and the impact on the antifungal activity of the peptide. The role of the 
E16 and the K13 residues of the Hst-5 sequence were investigated by single amino acid 
substitutions at these sites. The gel electrophoresis and mass spectrometry analysis 
demonstrated that some of the modifications led to a Sap-dependent response while 
others showed similar responses to both Sap9 and Sap2 (Figure 3.1 and Figure 3.3). The 
arginine substitution at the E16 site displayed a Sap-dependent response, with the E16R 
modification leading to enhanced resistance to proteolysis by Sap2 but decreased 




with the previously identified  preference of Sap9 for arginine [17]. On the other hand, 
the leucine substitution at the same site indicated no Sap-dependent response, with the 
modified peptide being more degraded than Hst-5 by both of the Saps. Sap2’s preference 
for leucine [22] could play a role in the modified peptide’s susceptibility to Sap2.  
Similarly to the E16R peptide, the K13H and K13E modifications resulted in more 
proteolysis by Sap9 than Sap2. The increased degradation of K13E may be due to the 
presence of the negatively charged glutamic acid residue on the C-terminal side of the 
R12 residue. Schild et al. previously reported enrichment of cleavage in peptides with an 
acidic amino acid C-terminal to an arginine or lysine [18]. Overall, with the exception of 
the E16L, the tested modifications were more susceptible to degradation by Sap9, even 
though Hst-5 showed a similar level of degradation between the two Saps at the tested 
concentrations (Figure 3.1). 
 The single residue modifications had a profound impact on the antifungal activity of 
the intact peptides (Figure 3.5) and the degradation fragments (Figure 3.7). While 
substitution of K13 with a histidine had no impact on the antifungal activity, introduction 
of a glutamic acid at this site led to a decrease in antifungal activity. This corroborates the 
decrease in antifungal activity observed by Tsai et al. for the same modification [38]. The 
preservation of the antifungal activity by the K13H modification at a comparable level to 
Hst-5 further supports the importance of the positive charge at this site, as previously 
suggestion by Tsai et al. [38], and demonstrates that the positive charge is more important 
than the specific residue at the K13 site.  
  Both of the E16 site modifications led to an increase in the antifungal activity, despite 




the previously tested substitution of glycine at the site, which led to significantly less 
antifungal activity [36]. Helmerhorst et al. also improved antifungal activity of modified 
Hst-5 fragments dhvar1 and dhvar2 by further substituting the glutamic acid with lysine 
[42]. The improved activity with arginine, leucine, and lysine substitutions but worsened 
activity with a glycine substitution suggests that identity of the residue at the site plays an 
important role for the antifungal activity. Residues with a positively charged or neutral 
side chain (larger than hydrogen) lead to better antifungal activity than residues with 
negatively charged side chains. It is also possible that by removing the negative charge, 
the antifungal activity of the N-terminal end of the peptide improved. The mass 
spectrometry analysis showed more N-terminal fragments for both E16R and E16L 
(Figure 3.3), which would contain the residues 4 – 15 fragment identified as the 
antifungal fragment [34] but not most of the residues in the amino acids 11 – 24 
antifungal fragment [33]. Even after incubation with higher concentration of Saps than 
used for samples in mass spectrometry analysis, the modified peptides retained a 
significant amount of antifungal activity. Therefore, the proteolysis by Saps likely did not 
cleave the active fragments of the each modified peptides.  
 In addition to single amino acid substitutions, this study also investigated whether 
individual modifications that lead to more resistance to Saps (K17R) and enhanced 
antifungal activity (K11R) can be combined into one peptide that has both of the 
enhanced properties. Previous studies have combined amino acid modifications to study 
the effect on antifungal activity of Hst-5 or Hst-5 fragments [34, 38], but no other work 
has attempted to combine positive improvements in two different properties. This goal 




peptide had significantly enhanced resistance to proteolysis by both Saps and C. albicans 
and showed no degradation around the R17 modified residue, as expected from the K17R 
modification. The antifungal activity of the intact peptide was at a level similar to that of 
the previously tested K11R peptide, demonstrating the positive effect on antifungal 
activity from that modification. Interestingly, the mass spectrometry analysis showed a 
shift in the cleavage sites of K11R-K17R compared to Hst-5, with more distinct cleavage 
sites in the N-terminal portion of the peptide, which was not previously observed in the 
individual modifications. The improvements observed with the K11R-K17R peptide 
show that it is possible to combine enhancements from individual modifications into one 
peptide.  
 The kinetic study with Sap9 on Hst-5, E16L, and K11R-K17R revealed that the 
residue substitutions do indeed affect the kinetics of proteolysis (Figure 3.4). While a 
kinetic degradation study on Hst-5 has been previously done with Saps [25] and with 
whole saliva [76], no previous study explored the effect of amino acid substitutions on 
the kinetics. The initial degradation of the Hst-5 and E16L peptides led to rapid 
accumulation of the amino acids 1 – 17 fragment, suggesting that the first cleavage of the 
peptides occurs C-terminal to the K17 site. Bochenska et al. observed a similar initial 
rapid accumulation of the same Hst-5 fragment during incubation  with Sap9 [25]. 
However, after 30 min, they recorded a decrease of the fragment [25], whereas in this 
study it accumulated throughout the study period. It is important to note, however, that 
the enzyme:substrate ratio, buffer, and pH used are different between the studies and the 
differences are likely to affect the results. Meanwhile, the amino acids 1 – 17 fragment 




E16L peptides, the proteolysis of K11R-K17R was at a slower rate and slowed down 
further over course of the study. The slowed kinetics may contribute to the increased 
resistance of the peptide to proteolysis. 
 In addition to showing the degradation of the intact peptides, the kinetic study also 
revealed interesting trends for degradation of the peptide fragments. The continued 
accumulation of the fragments or the steady state level of the fragments seen in Hst-5 and 
K11R-K17R samples suggest that these degradation fragments are robust and less 
targeted by Sap9. On the other hand, the fragments of E16L showed a decrease in 
abundance after an initial increase. All of the detected fragments contain the E16L 
modified site, which suggests that the residue modifications made the proteolytic 
fragments that contain the modified site more susceptible to Sap9. Therefore, the residue 
substitutions modify not only the degradation kinetics of the intact peptide but also the 
degradation kinetics of the cleavage fragments. 
 
3.5. Conclusion 
 The work in this chapter revealed that modifications to one or two amino acids of 
Hst-5 can significantly affect the kinetics of the proteolysis by Sap9. They can also 
impact the antifungal activity of both the intact peptide and its degradation fragments. 
Substitutions can increase the rate of degradation of the intact peptide, but simultaneously 
create fragments that are more robust with enhanced antifungal activity compared to the 
same fragments of the parent peptide, as demonstrated by the enhanced antifungal 
activity of the fragments of the E16L peptide. The K11R-K17R peptide also shows that 




into one peptide. Based on these findings, other modifications that lead to enhanced 
properties should be explored in combination to design a peptide that is even more robust 




Chapter 4: A simple and robust approach to immobilization of 
antibody fragments 
 
(This chapter is published in Ikonomova, S. P., He, Z. & Karlsson, A. J. (2016) A simple and robust 
approach to immobilization of antibody fragments, J Immunol Methods. 435, 7-16) 
 
4.1. Introduction 
 With increasing prevalence of drug-resistant strains, early detection of Candida 
infections is strongly desirable to enable the identification of the causative species and 
the start of appropriate treatment. However, the current gold standard for identifying 
Candida infections is through culturing of samples from infected patients, which can take 
two to three days to obtain a result [7]. This calls for a more rapid approach to identify 
Candida infections.  
 One alternative approach is use of an antibody array to capture and identify different 
species of Candida. Rather than full-sized antibody, small antibody fragments are seeing 
increasing use due to their ease of production in Escherichia coli. The single-chain 
variable fragment (scFv) is one such fragment, and it contains only the variable light 
chain and variable heavy chain domains of an IgG antibody connected by a flexible 
peptide linker. scFvs are one of the smallest IgG fragments that retain an antigen-binding 
capability similar to the full-length antibody [45], and their small size allows for easy 
insertion of their encoding DNA sequences into plasmids and fast replication in E. coli 
[46]. 
  To create an array using antibody fragments, the fragments must first be immobilized 
onto a surface with a method that will be versatile to multiple antibody fragments. 




optimizing the immobilization of only one or two antibody fragments at a time and use 
methods to detect the immobilization that are specific to the antibody fragment, 
diminishing the adaptability of the procedure to other antibodies [77]. The 
immobilization process also often first requires purification of the antibody fragments 
[78-81]. Purification of antibodies and other proteins can be time-consuming and costly, 
and the commonly used affinity purification methods may result in poor purities or 
yields. For example, affinity purification using a FLAG tag fusion gives high purity but 
the method is expensive and results in low yield of the desired protein; using a 
hexahistidine (6XHis) tag is far less expensive and gives a higher yield, but the product is 
plagued by low purity [82]. Elimination of the purification step would reduce cost and 
save time in immobilization protocols.  
 A robust and purification-free method for immobilizing antibody fragments was 
developed using the biotin-streptavidin interaction. It takes advantage of the ability of E. 
coli to attach biotin in vivo to a specific lysine residue of a native E. coli protein biotin 
carboxyl carrier protein (BCCP) [57] or a 15-amino acid minimal peptide substrate 
AviTag [61, 62]. Multiple scFvs from E. coli cell lysate were immobilized using the 
high-affinity biotin-streptavidin interaction and the capabilities of the BCCP and AviTag 
biotinylation sequences were evaluated under endogenous levels of biotin ligases and 
with overexpression of BirA. The results show that this approach leads to functional 






4.2. Materials and Methods 
4.2.1. Plasmid construction 
Table 4.1. Plasmids used to express scFvs and other proteins in this study. 
scFv/protein Source 
plasmid ref. 
Binding target Plasmid 
backbone 
Construct 




scFvD10 [84] [84-87] Bacteriophage lambda 























gpD [91, 92] N/A pET21a(+) pET21-gpD-His 
BirA Dorothy 
Beckett 
N/A pSPI03 pSPI03-BirA-His 
 
 The plasmids containing the scFvs and a C-terminal BCCP or AviTag (Table 4.1) 
were constructed by modifying the pAK400cb-SVV [59] plasmid. The plasmid backbone 
pSPI01B was created by digesting pAK400cb-SVV with NdeI and EcoRI to remove the 
gene encoding for the SVV protein. The pSPI01A backbone is analogous to pSPI01B, 
except the gene encoding for the BCCP tag was replaced with a sequence encoding for 
the AviTag [62] by using a pair of complementary primers. A SalI site was added to 
pSPI01B and pSPI01A to construct plasmids pSPI02B and pSPI02A, respectively, which 
allow for insertion of scFv genes containing an EcoRI site. The DNA encoding the scFvs 
in Table 1 was amplified by polymerase chain reaction (PCR) with a C-terminal FLAG 
tag, except for scFv3, scFv5, and scFv12, which were amplified with the N-terminal 




were amplified from source plasmids and inserted into both pSPI01B and pSPI01A 
between the NdeI and EcoRI sites. The DNA encoding scFv3, scFv5, and scFv12 was 
inserted into pSPI02B and pSPI02A between the NdeI and SalI sites. The scFv26-10 gene 
was inserted between NdeI and EcoRI of pSPI02B and pSPI02A. 
 Bacteriophage lambda head protein D (gpD), the binding target of scFvD-10, was 
expressed from the pET21a(+) plasmid (Novagen). The gpD gene was amplified from 
pAT222 [91, 92] and ligated between the NdeI and HindIII sites of pET21a(+), which 
contains a C-terminal 6XHis tag. The plasmid was transformed into BL21(DE3) cells for 
expression. 
 A plasmid containing BirA was used to increase the level of the enzyme present in 
cells producing biotinylated scFvs. The sequence encoding for the tac promoter, lac 
operator, and BirA enzyme with a C-terminal 6XHis tag was amplified from a plasmid 
gifted by Dorothy Beckett and inserted between the EcoRI and HindIII sites of the 
pMS421 plasmid to construct pSPI03-BirA-His. pSPI03-BirA-His was co-transformed 
into cells already containing the scFv plasmids in Table 1. The empty pMS421 plasmid 
was also co-transformed into cells expressing each scFv to serve as controls for the 
experiments with overexpressed BirA. 
4.2.2. scFv expression and Western blot analysis 
 The scFv fusions to biotinylation sequences were produced in E.coli MC4100 cells, 
except in experiments involving co-expression of BirA. For experiments involving co-
expression of BirA BL21 cells were used, because MC4100 cells have resistance to the 
streptomycin antibiotic required for maintenance of pMS421-based plasmids. Cultures 




chloramphenicol and 25 μg/mL streptomycin). Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to 100 μM and biotin to 5 μM were then added [59, 62], and protein expression 
was induced overnight at 20 °C. After expression, the cultures were harvested at 4 °C, 
and cell pellets were stored at -20 °C until use. To obtain cell lysates containing 
biotinylated scFvs, thawed cell pellets were lysed with BugBuster Master Mix (EMD 
Millipore) following the manufacturer’s protocol. A 5 kDa molecular weight cut-off 
column (GE) was used to remove excess biotin and exchange the buffer to phosphate-
buffered saline (PBS). The total protein concentration of the cell lysates was determined 
by measuring absorbance at 280 nm using a Nanodrop 2000 (Thermo Scientific), which 
assumes 1 absorbance unit = 1 mg total protein/mL. 
 For Western blot analysis, proteins in cell lysates were separated by SDS-PAGE on 
Any kD Mini-PROTEAN TGX gels (Bio-Rad) and detected using standard Western 
blotting protocols. The separated proteins were transferred onto polyvinyl difluoride 
(PVDF) membranes and stained with a horseradish peroxidase (HRP)-conjugated anti-
FLAG antibody (Sigma) to compare expression level or with an HRP-conjugated anti-
biotin antibody (Abcam) to detect biotinylation. Stained membranes were incubated with 
Clarity Western ECL substrate (Bio-Rad), and chemiluminescence was imaged on a 
ChemiDoc MP imaging system (Bio-Rad). 
4.2.3. Streptavidin gel-retardation assay 
 To get an estimate of biotinylation efficiency, a method was adapted from Predonzani 
et al. [93]. Boiled samples of scFv13R4 and scFvD10 lysates mixed with SDS-PAGE 
loading buffer were incubated with or without streptavidin (NEB) for 1 hour at 4 °C. 




The proteins were transferred to a PVDF membrane and detected with an HRP-
conjugated anti-FLAG antibody. Biotinylated scFvs bind to streptavidin and travel more 
slowly [93], appearing at a higher molecular weight than the scFvs alone. Densitometry 
analysis was done on the blots to estimate the biotinylation efficiency based on the 
decrease in the band volume at the unbound scFv molecular weight due to binding to 
streptavidin. Biotinylation experiments were performed in triplicate for three biological 
replicates. 
4.2.4. gpD expression and preparation 
 The gpD protein was expressed in E. coli BL21(DE3) cells. Cultures were grown to 
mid-log phase at 37 °C with 100 μg/mL ampicillin. IPTG was then added at 100 μM, and 
protein expression was induced overnight at 20 °C. Cells were harvested and lysed using 
protocols analogous to those for harvesting scFvs (Section 2.2). Desalting columns 
(Thermo Fisher Scientific) were used to exchange the buffer to PBS. Lysates were then 
filtered through 100 kDa molecular weight cut-off columns (GE) to clear the lysate of 
large components and concentrated with 3 kDa molecular weight cut-off columns (GE). 
4.2.5. Purification of scFvs 
 For evaluating immobilization of purified scFvs, the BCCP and AviTag constructs of 
scFv13R4 and scFvD10 were purified using the FLAG Immunoprecipitation Kit (Sigma) 
following the manufacturer’s protocol. The concentration of each purified product was 
calculated by measuring absorbance at 280 nm, assuming all protein within the sample 
was the purified scFv construct. Extinction coefficients for the constructs were calculated 




for scFv13R4-BCCP, 50100 M-1 cm-1  for scFv13R4-AviTag, 47580 M-1 cm-1 for 
scFvD10-BCCP, and 51590 M-1 cm-1 for scFvD10-AviTag. The purity of the samples 
was confirmed by running SDS-PAGE on the samples and staining the proteins with Bio-
Safe Coomassie stain (Bio-Rad).  
4.2.6. Enzyme-linked immunosorbent assay  
 The immobilization and the antigen-binding capabilities of the scFvs were assessed 
using an enzyme-linked immunosorbent assay (ELISA) done in triplicate. The scFvs 
were immobilized onto 96-well high-binding polystyrene plates (Corning) coated with 
streptavidin. Streptavidin-coated plates were prepared based on the method described by 
Winkler et al. [60] In each well of 96-well plates, 50 μL of 0.1 μg/μL streptavidin (NEB) 
was loaded, and the water was evaporated overnight in a 37 °C incubator. The dried 
plates were covered and stored at 4 °C until use, typically within one week. Plates were 
washed with PBS containing 0.1% Tween 20 (PBST) immediately prior to use in assays. 
 For immobilization assays, cell lysates or purified scFvs were serially diluted two-
fold with PBST containing 0.5% milk. The diluted scFvs (50 μL/well) were loaded onto 
washed streptavidin-coated plates, and the plates were incubated for 45 minutes at room 
temperature. The immobilized scFvs were then incubated with an HRP-conjugated anti-
FLAG antibody for 1 hour at room temperature. After each incubation step, the plates 
were washed with PBST four times to remove any unbound components. Plates were 
then incubated in the dark for 30 minutes with o-phenylenediamine dihydrochloride HRP 
substrate (Sigma), and the enzyme-substrate reaction was quenched with 3 M H2SO4. The 




 The ability of the immobilized scFv13R4-BCCP, scFv13R4-AviTag, and scFvD10-
BCCP to bind to their targets (β-galactosidase for scFv13R4 and gpD for scFvD10) was 
evaluated using a procedure similar to the process for detecting immobilization. Constant 
concentrations of lysate (1 μg/μL of total protein) and purified scFvs (0.0125 μg/μL) 
were incubated on streptavidin-coated plates to obtain a surface saturated with scFv. 
After incubating for 45 minutes and washing with PBST, serial dilutions (0 – 50 μg/mL) 
of commercial β-galactosidase (Sigma) and serial dilutions (0 – 8 μg/μL total protein) of 
lysate containing 6XHis-tagged gpD in PBST with 0.5% milk were loaded in the wells 
(50 μL/well) with scFv13R4 and scFvD10 constructs, respectively. The plates were 
incubated for 1 hour.  The bound β-galactosidase was detected with an HRP-conjugated 
anti-β-galactosidase antibody (Abcam), and the bound gpD was detected with an HRP-
conjugated rabbit anti-6XHis antibody (Abcam) using protocols analogous to those for 
detecting immobilization of the scFv constructs. scFvD10-AviTag was not tested, 
because we found that the anti-6XHis antibody used to detect bound gpD cross-reacts 
with the AviTag constructs of scFvD10, scFv13R4, and scFv26-10.  
4.2.7. Stability assay 
 To determine the length of time that immobilized scFvs can be stored while 
maintaining functionality, 0.1 μg/μL of scFv13R4-BCCP and scFv13R4-AviTag cell 
lysates and 1 μg/μL of scFvD10-BCCP cell lysates were incubated in each well as 
described in Section 2.6 and washed with PBST. PBST containing 0.5% milk or 50% 
glycerol in water was then added to the wells. Plates were covered with a lid, wrapped in 
Parafilm, and stored at 4 °C or -20 °C. Over a 100-day period, plates were removed from 
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scFv5, and scFv12, however, the BCCP constructs were more highly expressed and 
higher levels of the biotinylated BCCP constructs were present than for the AviTag 
constructs. The relatively low expression of these scFvs compared to scFv13R4 and 
scFvD10 was expected, since scFv13R4 and scFvD10 have been engineered for high 
levels of cytoplasmic solubility [83, 84], whereas scFv3, scFv5, and scFv12 have not 
been engineered for solubility [88, 89]. The lower molecular weight bands seen in both 
blots appear to be degradation products containing the biotinylation fusion tags and the 
FLAG tag. Although the degradation products were present, in all but one case (scFv26-
10) the scFvs were the most abundant biotinylated protein in the sample. The successful 
expression and biotinylation of various scFvs shows the potential for wide applicability 
of in vivo biotinylation of scFvs for protocols that take advantage of the biotin-
streptavidin interaction.  
4.3.2. scFvs are immobilized directly from cell lysate 
 After establishing that the scFvs were expressed and biotinylated in vivo, we 
evaluated their immobilization onto streptavidin-coated 96-well plates. The 
immobilization of the scFvs on the plates was quantified through an ELISA to detect the 
FLAG tag at the C-terminal (scFv13R4, scFvD10, scFv26-10) or N-terminal (scFv3, 
scFv5, scFv12) end of the scFv (Figure 4.1). As the data in Figure 4.3 show, all scFvs 
were successfully immobilized, though the level of immobilization varied. scFv 
constructs with BCCP exhibited a higher level of immobilization than scFv constructs 
with the AviTag at lower total protein concentrations. The one exception to this was 
scFv26-10, which showed greater immobilization with the AviTag, but this could be due 
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difference between BCCP and AviTag tags, despite almost complete biotinylation with 
BirA. This suggests that the variation in immobilization level between constructs with 
different biotinylation tags is not fully explained by differences in biotinylation of the 
tags, and difference in the biotinylation tags may still play a role. 
4.3.5. Immobilized scFvs maintain the ability to bind antigen 
 Unlike non-oriented immobilization where the antigen-binding site may be disrupted 
by the immobilization process [48], we predicted that the oriented immobilization with 
biotin-streptavidin via site-specific biotinylation would not diminish the ability of an 
scFv to bind to its target. To ensure that immobilized scFvs retain functionality, we tested 
the ability of immobilized scFv13R4 (with the BCCP and AviTag biotinylation fusions) 
to bind to its antigen β-galactosidase, which is commercially available, and the ability of 
immobilized scFvD10 (with BCCP biotinylation tag) to bind gpD protein, which we 
produced recombinantly. scFvD10-AviTag was not included in this experiment, because 
the anti-6XHis antibody we used to detect gpD cross reacts with the AviTag in this 
construct. Using data from Figure 4.3 and Figure 4.5, scFv constructs in cell lysate and 
purified scFv constructs were immobilized at a concentration leading to saturation of the 
surface with scFvs (0.0125 μg purified protein/μL for purified constructs and 1 μg total 
protein/μL for cell lysates). We observed an increase in binding to the antigens with an 
increasing amount of antigen (Figure 4.8), which shows that the scFvs maintained their 
ability to bind to their target. For scFv13R4, both the BCCP and AviTag constructs 
showed similar levels of signal at all β-galactosidase concentrations, indicating that the 
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BCCP, scFv13R4-AviTag, and scFvD10-BCCP stored at both temperatures and in both 
storage buffers were still able to bind their respective targets. Based on the strong 
absorbance signal at 100 days, we expect that the immobilized scFvs would maintain 
their functionality beyond this time point. It must be noted that although the absorbance 
levels at different temperatures and different storage solutions at each time point can be 
compared, the levels at different time points cannot be strictly compared due to 
inconsistencies in the HRP substrate between time points. However, the antigen-
dependent binding signal clearly shows that the immobilized scFvs maintain antigen-
binding after prolonged storage. 
 
4.4. Discussion 
 We studied the versatility of using the biotin-streptavidin interaction to immobilize 
multiple scFvs onto a surface directly from E. coli cell lysates. No purification of the 
scFvs is needed in this process, because the immobilization step acts as a purification 
step. Only biotinylated proteins bind to the streptavidin-coated surface, while other 
proteins in the cell lysate are washed off. Our approach to scFv immobilization is further 
simplified by using in vivo biotinylation in our protein production host, E. coli. We fused 
biotinylation tags to the scFvs and took advantage of the native biotinylation machinery 
of E. coli, eliminating the need for additional steps and reagents involved with in vitro 
biotinylation methods [62]. The in vivo biotinylation of BCCP and the AviTag allows 
immobilization that is also site-specific, in contrast to the random immobilization site that 
is typical for immobilization via in vitro biotinylation. Our results extend prior work [77, 




and target antigens can be achieved using a single, straightforward protocol and by 
evaluating the suitability of different biotinylation sequences for scFv immobilization. 
 We tested two different biotinylation sequences, BCCP and the AviTag, to determine 
whether one allows for better expression and immobilization of the scFvs when used with 
endogenous levels of biotin ligases. We initially predicted the AviTag to lead to better 
immobilization, because we expected its smaller size would cause less steric hindrance. 
We did see better expression for the AviTag constructs of scFv13R4, scFvD10, and 
scFv26-10 (Figure 4.2), consistent with our expectation. However, scFvs constructs from 
both cell lysates and purified samples showed more immobilization with BCCP when the 
same concentration (below surface saturation) was used for immobilization (Figure 4.3 
and Figure 4.5).  
 The possible role of biotinylation efficiency of the tags was explored by 
overexpressing the biotin ligase BirA. While enhanced biotinylation did improve 
immobilization of scFvD10-AviTag to the level of its BCCP analog, scFv13R4 still 
showed a difference in immobilization level between the biotinylation tags (Figure 4.7), 
indicating that biotinylation efficiency is only partially responsible for differences in 
immobilization. The difference in the size of the biotinylation tags may also contribute to 
the difference. Although the smaller AviTag allows some constructs to be expressed 
better, the biotin attached to the AviTag may not be as accessible for streptavidin binding 
in some scFv constructs as the biotin attached to the BCCP constructs. The larger BCCP 
protein may function as a linker between the biotin and the scFv to improve the 
accessibility of the biotin to the streptavidin on the surface. Previous studies on linkers 




length of a linker can affect the binding affinity of a protein. For example, longer linker 
between two scFv variable chains increased affinity [95] and addition of glycyl linker 
between target and FLAG tag improved immunoprecipitation efficiency [96] . These 
examples support the possibility that the larger BCCP tag could improve the interaction 
of biotin with streptavidin in our results. The difference in the tag does not appear to 
affect the functionality of the scFvs, however, as both constructs of purified scFv13R4 
showed similar binding to β-galactosidase when the surface was saturated with scFv 
(Figure 4.8). 
 Our results show that, while BirA overexpression is advantageous in improving the 
biotinylation level of AviTag constructs, BirA overexpression for BCCP constructs 
unnecessarily complicates the system without providing a significant advantage in 
immobilization. Using BCCP as the biotinylation tag without overexpressing BirA allows 
the system to be simpler, by reducing the number of plasmids required and eliminating 
the need for a second antibiotic.  
 
4.5. Conclusion 
 Our method for immobilizing scFvs is a simple, robust, and versatile method based 
on the high-affinity biotin-streptavidin interaction. Few reagents are required beyond 
typical bacterial culture reagents, and no specialized techniques are required for 
immobilizing the scFvs or detecting immobilization. Elimination of purification steps 
reduces the time and cost of sample preparation for immobilization without 
compromising antigen-binding. The method is adaptable to a variety of scFvs, as we 




immobilized scFvs still binding to targets for at least 100 days after immobilization. The 
simplicity and ease of our approach make it appealing for many applications involving 
immobilization of scFvs, such as screening interactions of scFvs with various targets or 
screening for off-target interactions. For example, it could be used to immobilize scFvs 
for surface plasmon resonance assays without undertaking a separate purification step, 
since the scFvs would be purified during binding of the biotinylated scFvs to a 
streptavidin-coated surface. The versatility of the method will also make it a widely 
applicable tool for future research and development involving antibody fragment 
immobilization, such as in microfluidic device development, pathogen or toxin detection, 















 Fusion of proteins can lead to enhancement in functionality, solubility, and binding 
affinity [95, 97, 98]. A common method to create a fusion protein is with peptide linkers. 
Furthermore, the linker length has been shown to affect the activity and expression of the 
fused proteins [99-101]. The three main types of commonly used peptide linkers are 
flexible, rigid, and cleavable linkers. Flexible linkers such as (G4S)n, where n denotes the 
number of repeats of the sequence, are typically used to connect the VH and VL domains 
of single-chain variable fragments (scFvs). The flexibility allows the linker to be applied 
as a method to separate domains [97] or improve their interaction [102]. While the 
distance between two fusion partners may fluctuate with the flexible linkers, more fixed 
distance can be maintained with rigid linkers such as the α-helix forming (EA3K)n linker 
[103]. Finally, unlike the flexible and rigid linkers that are generally designed to have 
proteolytic stability, cleavable linkers instead take advantage of in vivo processes, such as 
reduction of disulfide bonds, to release functional domains [102]. The type of linker that 
is used depends on the desired role of the linker in the fusion protein design.  
 Another possible application of a linker is to improve binding of an immobilized 
protein to its target by expanding the distance between the binding site and the point of 
immobilization. Previous work in Chapter 4 developed a simple, purification-free scFv 




tags—the biotin carboxyl carrier protein (BCCP) or AviTag—that are directly fused to 
scFvs for in vivo biotinylation [75]. In most of the cases, the BCCP fusion of the tested 
scFvs immobilized better than the corresponding AviTag fusion of the scFvs. Co-
expression of the biotin ligase BirA with the scFvs enhanced the biotinylation efficiency 
of the AviTag constructs and improved their immobilization, but the effect was scFv-
dependent. For example, the constructs of scFv13R4 still showed significant difference in 
immobilization between the biotinylation tags, despite enhanced biotinylation efficiency 
of the AviTag construct [75]. One theory for the difference is that the FLAG tag used to 
detect the immobilization is not as easily accessible in the AviTag constructs as in the 
BCCP constructs, because the larger BCCP biotinylation tag acts as a linker that 
distances the FLAG tag further from the immobilization surface and enhance its 
accessibility. To test this theory, flexible peptide linkers of various lengths and a rigid 
linker were inserted between scFv13R4 and the biotinylation tags, and the effect on 
immobilization and expression of the scFvs was evaluated. scFv5, which previously 
showed poor expression and immobilization of its AviTag construct [75] was also tested 
to determine if the effect of linkers is scFv- or expression-dependent. The study found 
that while the linkers had a limited effect on the scFv constructs that were able to reach 
saturated immobilization levels in the work in Chapter 4 (both of scFv13R4 constructs 
and the BCCP construct of scFv5), the linkers improved the immobilization of the 
AviTag-fusion of scFv5 that previously showed a low immobilization level. Linkers can 






5.2. Materials and Methods 
5.2.1. Linker plasmid construction 
 To test the effect of linkers on expression and immobilization, flexible (G4S)n 
linkers—with variable lengths of n = 1, 3, and 5—and one rigid linker (EA3K)3 were 
incorporated into the fusion of scFv13R4 to the BCCP or AviTag biotinylation tag 
between the scFv and the tag. Pairs of complementary primers that encode for each linker 
were designed and inserted between the SalI and EcoRI cut-sites of pSPI02B and 
pSPI02A plasmid backbones to create new backbones with linkers N-terminal to the 
BCCP and AviTag, respectively (Table 5.1). DNA encoding for scFv13R4 was amplified 
by polymerase chain reaction (PCR) with a C-terminal FLAG tag and inserted between 
 






scFv13R4 None BCCP pSPI02B scFv13R4-BCCP
(G4S)1 BCCP pSPI03B scFv13R4-(G4S)1-BCCP
(G4S)3 BCCP pSPI04B scFv13R4-(G4S)3-BCCP
(G4S)5 BCCP pSPI05B scFv13R4-(G4S)5-BCCP
(EA3K)3 BCCP pSPI07B scFv13R4-(EA3K)3-BCCP
None AviTag pSPI02A scFv13R4-AviTag
(G4S)1 AviTag pSPI03A scFv13R4-(G4S)1-AviTag
(G4S)3 AviTag pSPI04A scFv13R4-(G4S)3-AviTag
(G4S)5 AviTag pSPI05A scFv13R4-(G4S)5-AviTag
(EA3K)3 AviTag pSPI07A scFv13R4-(EA3K)3-AviTag
scFv5 None BCCP pSPI02B scFv5-BCCP
(G4S)3 BCCP pSPI04B scFv5-(G4S)3-BCCP
(EA3K)3 BCCP pSPI07B scFv5-(EA3K)3-BCCP
None AviTag pSPI02A scFv5-AviTag
(G4S)3 AviTag pSPI04A scFv5-(G4S)3-AviTag




the NdeI and SalI cut-sites N-terminal to the linker or, if no linker was present, N-
terminal to the biotinylation tag. To test whether the effect of linkers is scFv specific, 
scFv5, whose AviTag construct previously showed low immobilization [75], was 
amplified and inserted into the backbones with (G4S)3 and (EA3K)3 linkers. scFv5 has an 
N-terminal FLAG tag, as it was present in the original source plasmid.  
5.2.2. scFv expression 
 The scFv constructs with or without linkers were produced in E. coli BL21 cells. 
Overnight cultures were subcultured and grown at 37 °C with 20 μg/mL chloramphenicol 
for plasmid maintenance. Once the cultures reached mid-log phase, isopropyl β-D-1-
thiogalactopyranoside (to 100 μM) and biotin (to 5μM) were added [59, 62] to induce 
expression and allow biotinylation. Cultures were grown overnight at 20 °C. Cells were 
then harvested at 4 °C, and the cell pellets were frozen at -20 °C until needed. To extract 
the biotinylated scFvs, cell pellets were thawed and lysed with BugBuster Master Mix, 
following the manufacturer’s protocol. To remove excess biotin and exchange the buffer 
to phosphate-buffered saline (PBS), each lysate was put in a 5 kDa molecular weight cut-
off column (GE). The total protein concentrations in the cell lysates before and after 
buffer exchange were quantified with the A280 method on the Nanodrop 2000 (Thermo 
Scientific), with the assumption of 1 absorbance unit = 1 mg total protein/mL. 
5.2.3. Western blot for expression analysis 
 Western blot analysis was used to quantify the effect of the linkers on the expression 
of the scFvs. After cell lysis with the BugBuster Master Mix, the lysates were mixed with 




Spring Harbor protocol) and boiled for 5 min at 98 °C. Samples were then run on Any kD 
Mini-PROTEAN TGX gels (Bio-Rad) to separate the proteins by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). The separated scFvs were detected 
using standard Western blotting protocols. After SDS-PAGE, the proteins were 
transferred onto polyvinyl difluoride (PVDF) membranes, and the membranes were 
blocked in Tris-buffered saline with 0.1% Tween 20 (TBST) and 5% milk. To detect the 
expression level of the scFvs, the membranes were washed and stained with horse radish 
peroxidase (HRP)-conjugated anti-FLAG antibody (Sigma). Antibody-stained PVDF 
membranes were developed with the Clarity Western ECL substrate (Bio-Rad), and the 
resulting chemiluminescence was detected on a ChemiDoc MP imaging system. The 
level of expression was quantified through densitometric analysis on ImageLab software 
(Bio-Rad).  
5.2.4. Enzyme-linked immunosorbent assay for immobilization analysis 
 The effectiveness of immobilization of the biotinylated scFvs was quantified using an 
enzyme-linked immunosorbent assay (ELISA). High-binding 96-well polystyrene plates 
(Corning) were coated with streptavidin, as previously described [75]. PBS buffer-
exchanged cell lysates were serially diluted in PBS with 0.1% Tween 20 (PBST) with 
0.5% milk and loaded onto streptavidin-coated plates (50 μL/well), which were washed 
with PBST prior to loading of the samples. After 45 min of incubation, unbound scFvs 
were washed off with PBST, and the immobilized scFvs were incubated for 1 h with an 
anti-FLAG antibody (HRP-conjugated). Unbound antibody was washed off and 200 μL 
of o-phenylenediamine dihydrochloride HRP substrate (Sigma) was added to each well to 




added to quench the reaction. The level of immobilization was quantified using 
absorbance at 492 nm, measured on a plate reader (Epoch, Bio-Tek). 
 
5.3. Results 
 This study investigated whether the distance between the antibody fragment and the 
point of immobilization affects the immobilization of biotinylated scFvs to a streptavidin-
coated surface. The distance between the scFv and the biotinylation site was lengthened 
through addition of flexible linkers of various length—(G4S)1,  (G4S)3, and (G4S)5—and a 
rigid linker (EA3K)3 between the scFv and the biotinylation tags, BCCP and AviTag, that 
are C-terminal to the  scFv. scFv13R4 was chosen as the first test candidate, as the BCCP 
fusion and the AviTag fusion of the antibody fragment previously showed a difference in 
immobilization [75]. The difference was present even after the biotinylation efficiency of 
the AviTag construct was enhanced with BirA enzyme. To determine if the effects of the 
linkers extend to other scFvs or are scFv specific, one of the flexible linkers (G4S)3 and 
the rigid linker (EA3K)3 were also tested with another scFv, scFv5 [89].  
5.3.1. scFv13R4 constructs are robust and unaffected by linkers 
 The effect of the linkers on the immobilization of scFv13R4 was assessed on 
streptavidin coated 96-well plates using ELISAs. The extent of immobilization was 
quantified by detection of the FLAG tag at the C-terminal end of the scFv13R4. In 
agreement with the previous study [75], the BCCP constructs immobilized better than the 
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 A number of previous studies have used peptide linkers to enhance activity and 
expression of fusion proteins [102]; however, limited studies have used them as a tool to 
enhance binding onto a surface [104] or to functionalized beads [96, 99]. This study 
investigated the effect of flexible and rigid linkers on immobilization of scFvs using the 
biotin-streptavidin interaction. Flexible linkers (G4S)n, with n = 1, 3, or 5, or a rigid linker 
(EA3K)3 were evaluated with scFv13R4, and the (G4S)3  linker and the (EA3K)3 linker 
were also tested in scFv5. The immobilization of the AviTag fusion of scFv5 was 
significantly enhanced by the introduction of the linkers (Figure 5.2). At the same time, 
the linkers had no effect on the immobilization of the scFv13R4 constructs with either 
biotinylation tag (Figure 5.1) or the BCCP constructs of scFv5 (Figure 5.2), so the 
influence of the linker is not universal to all scFv constructs. The addition of linker has 
no negative influence on immobilization, therefore, it could be included as a default part 
of a construct without a potential to decrease immobilization.  
 Initially, the improved immobilization signal was hypothesized to be due to enhanced 
expression of the scFv5-AviTag constructs with a linker, as previous studies have 
demonstrated enhanced expression of protein fusions due to linkers [101, 105]. However, 
Western blot analysis with an anti-FLAG antibody showed that the linkers did not 
increase the expression of either scFv (Figure 5.3 and Figure 5.4). The lack of greater 
expression due to linkers indicates the immobilization improvements observed with 
scFv5 constructs are not due simply having a higher level of soluble scFv-biotinylation 




 The size of the fused components may explain the significant shift in immobilization 
of scFv5 fused to the AviTag compared to BCCP. With 15 residues, the AviTag 
biotinylation tag [62] is much smaller than the 87 residues of BCCP [63]. Therefore, the 
addition of 15 residues from the three repeats of the linker sequence likely has a larger 
impact on the AviTag constructs by greatly increasing the distance between the surface 
and the scFv. However, the immobilization of scFv13R4 does not follow this trend, and, 
in fact, the AviTag-fusions showed very little variability among the linkers tested. 
Alternatively, the linkers may simply affect various scFvs fusions differently, improving 
the immobilization of one yet having no effect on the other. 
 
5.5. Conclusion 
 This study demonstrated that peptide linkers have neutral to positive effect on 
immobilization. The linkers can enhance immobilization of scFv that show poor 
immobilization without a linker while having no adverse effect on a scFv that show high 
immobilization. Insertion of an even longer linker could lead to an AviTag construct of 
scFv5 that immobilizes at similar level to the BCCP construct. Study with other types of 
linkers on more scFvs could give more insight on whether these observations can be 










 This dissertation demonstrated the use of protein engineering approaches to study 
topics related to a Candida fungal pathogen. Chapter 2 and Chapter 3 looked at 
improvements toward treatment of C. albicans infections through study of the antifungal 
peptide histatin 5 (Hst-5). The chapters explored the interactions between Hst-5 and the 
Saps produced by C. albicans by designing amino acid modifications that alter the 
proteolytic susceptibility to the Saps as well as the antifungal activity of the peptide. The 
effect of modification on both of these properties was explored unlike the previous 
studies, which mainly focused on effect on antifungal activity. The findings led to 
designing of a modified peptide with not only enhanced resistance to Saps (K17R, K17L) 
or improved antifungal activity (K11R), but with both of the properties improved (K11R-
K17R). Additionally, during the course of the study, an optical density-based method to 
test the antifungal activity the peptides was developed. The method allows quicker and 
easier comparisons of the antifungal activity of multiple peptides simultaneously, at 
broad concentration ranges, compared the typically used colony-counting method and the 
results of the two methods are comparable (Figure A.3) Chapter 4 and Chapter 5 used 
protein engineering approaches to work towards improvements in diagnostics. The 
simple and versatile scFv immobilization method developed in these chapters could be 





 Based on the work in this thesis, a number of additional experiments could be 
done. This recommended future work is focused on further characterizing the modified 
Hst-5 peptides and improving their potential as a therapeutic to treat Candida infections. 
 
6.1. Further characterization of the Hst-5 variants 
6.1.1. Additional modifications to Hst-5 
 The single amino acid substitution studies on Hst-5 in Chapter 2 and Chapter 3 
discovered modifications that increase the resistance to proteolysis by Saps and 
C. albicans (K17R, K17L) or improve the antifungal activity (K11R, E16R, E16L). 
Combination of modifications from each improved property led to a variant of Hst-5 with 
both of the enhanced properties (K11R-K17R). The effect seen with K11R-K17R opens 
the possibility of exploring other combinations of the peptide modifications with 
enhanced properties. One recommended modification is the K11R-E16R-K17R (Table 
6.1). While E16R modification was more susceptible to proteolysis by Sap9, it showed 
enhanced resistance to Sap2. Furthermore, it showed improved antifungal activity despite 
the degradation. By adding this substation to the K11R-K17R peptide, the modified 
peptide could have even more augmented antifungal activity against C. albicans. If the 
triple-modified peptide successfully shows further improvement in activity, a study with 
E16R-K17R modified peptide could give more insight into how each modification affects 







Table 6.1. The amino acid sequence of Hst-5 and variants for future studies. The modified 
residues are highlighted in blue. 
Name
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Hst-5 D S H A K R H H G Y K R K F H E K H H S H R G Y
K11R-E16R-K17R D S H A K R H H G Y R R K F H R R H H S H R G Y
E16R-K17R D S H A K R H H G Y K R K F H R R H H S H R G Y
Sequence
 
6.1.2. Proteolysis resistance in saliva 
 Hst-5 and the rest of the family of histatins are secreted by the parotid and 
submandibular glands [27] and help fight C. albicans infection in the mouth. However, 
saliva is composed of various other proteins that contribute to innate immunity [23, 24] 
and have a synergetic effect among them [106]. The enzymes in saliva can also cleave 
histatins, as demonstrated by kinetic studies on proteolysis of Hst-5 by whole saliva [76, 
107]. Therefore, it is important to investigate the stability of the Hst-5 variants in whole 
saliva. Inspired by the work of Sun et al. [76], the modified peptides could be added to 
pooled samples of whole saliva and the decrease in the intact peptide monitored through 
mass spectrometry. Isotopically labeling multiple carbons in the peptides to 13C can give 
a better quantification with mass spectrometry for the intact peptide remaining. The 
modifications that increased resistance to proteolysis by Saps could also increase 
resistance to the other proteolytic enzymes, or, alternatively, make them more 
susceptible. Gaining such understanding can aid in improving methods to introduce the 
modified peptides to the oral cavity so that the activity of the peptide is not immediately 




6.1.3. Cytotoxicity to oral epithelial cells 
 In addition to ensuring that the variants of Hst-5 remain functional in saliva, it is also 
important to verify that the modifications do not cause toxicity to oral epithelial cells. 
Natural antifungal peptides do not have significant toxicity to host cells [68]. While 
hemolytic activities of Hst-5 variants have been reported [35, 42, 108], the ratio of the 
concentration at which 50% hemolysis is observed (HC50) to MIC50 were higher for all 
Hst-5 variants than Hst-5 [42]. This suggests that the peptides are more selective for 
C. albicans. However, the hemolysis assay is not enough to evaluate the potential toxicity 
of antimicrobial peptides. A recent study on the anti-Candida activity of uperin 3.6 and 
its variants found that, while the peptides had no hemolytic activity to erythrocytes, they 
were highly toxic to human vaginal and esophagial epithelial cells [109]. Therefore, in 
addition to the hemolysis assay, the potential cytotoxicity of the Hst-5 variants to oral 
epithelial cells should be evaluated.  
6.1.4. In vivo efficacy with murine oral candidiasis model 
 Once the cytotoxicity of the peptides to epithelial cells has been evaluated, the in vivo 
efficacies of the peptides need to be examined to determine whether the improvements 
observed in in vitro assays are translated to in vivo results. While numerous studies have 
looked at the antifungal activity of Hst-5, its fragments, or their variants through in vitro 
assays [33-39], limited ex vivo or in vivo studies have been done [110, 111]. Kong et al. 
recently demonstrated that Hst-5 can be delivered to mice with oral candidiasis by 
formulating the peptide into a bioadhesive hydrogel [71]. Dr. Mary Ann Jabra-Rizk 
(University of Maryland Dental School) used this hydrogel formulation to test the 
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 With the steady-state structure in an aqueous environment determined, the peptide 
can now be placed a short distance above a bilayer of phospholipids emulating the cell 
membrane. Changes in its structural characteristics can be monitored as it approaches the 
phospholipid bilayer to gain a structural understanding of the peptide near the cell 
membrane. 
6.2.2. Structural determination with NMR 
 Previous studies have determined the structures of Sap1 [13], Sap2 [15, 119], Sap3 
[120], and Sap5 [13]. However, structures on the rest of the Saps, including Sap9, have 
not yet been elucidated. Furthermore, most of the available Saps structures are in a 
complex with an inhibitor, most commonly pepstatin A, and no structural determination 
of a Sap bound to an antifungal peptide like Hst-5 has been done. The structure of free 
Sap9 and Sap9 in complex with Hst-5 could be determined through NMR or X-ray 
diffraction of a crystalized sample. If the structural determination of the Sap-peptide 
complex is successful with Hst-5, the study can be expanded to include the variants of 
Hst-5 and evaluate how the peptide modifications may affect binding.   
6.2.3. Peptide and Sap docking simulation 
 While the structural determination of Sap9 with NMR or X-ray diffraction should be 
feasible, the structure of Sap in complex with Hst-5 may be difficult to discern if the time 
the peptide is in the binding pocket of the Sap is too short. Alternatively, once the 
structure of Sap9 has been determined, a docking simulation study could be done instead. 
Lum et al. have successfully demonstrated docking of their synthetic peptides with Sap1 




information on how the peptide aligns within the binding pocket of Sap9 and could 
provide insight into why some variants of Hst-5 are more susceptible to proteolysis by 
Saps than the others. 
 The recommended further characterization of Hst-5 variants and structural studies of 
Hst-5 will provide a more comprehensive understanding of the peptide’s interaction with 
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